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CHAPTER I 
INTRODUCTION 
Lung Cancer - the statistics 
Global cancer statistics indicate that lung cancer is responsible for over 1 million 
deaths each year (Siegel, Naishadham et al. 2012). According to the cancer statistics in 
US, it is estimated that 221,130 new patients were diagnosed with lung cancer in 2011, 
accounting for about 14% of cancer diagnoses. The incidence rate is declining 
significantly in men, from a high of 102.1 cases per 100,000 in 1984 to 71.8 cases in 
2007. In women, the rate has begun to decrease after a long period of increase.  Even 
though the incidence of lung cancer is second to prostrate in case of males and breast in 
case of females the trend of death is different. Lung cancer accounts for more deaths than 
any other cancer in both men and women. An estimated 156,940 deaths, accounting for 
about 27% of all cancer deaths, were expected to occur in 2011. For more than a decade 
since 1987, more women have died each year from lung cancer than from breast cancer. 
From Figure1 it is clear that the decrease in death rates began in men in 1991. The 
decrease in death rates in men accelerated to 3.0% per year in 2005. Female lung cancer 
death rates have been decreasing by 0.9% per year since 2003 after continuously 
increasing since at least 1930.  The difference between the incidence rates and the death 
rates, with regard to lung cancer, clearly designates the improvements we need to make 
regarding the treatment of lung cancer by knowing more about lung cancer biology. 
Gender differences in lung cancer mortality patterns reflect historical differences in 
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uptake and reduction of cigarette smoking between men and women over the past 50 
years (Siegel, Naishadham et al. 2012). 
 
 
 
 
 
 
 
 
Figure 1.  Trend of cigarette consumption and lung cancer deaths. 
As a result of the cigarette smoking epidemic, lung cancer death rates showed a steady 
increase through 1990, then began to decline among men. The lung cancer death rate 
among US women, who began regular cigarette smoking later than men, has begun to 
plateau after increasing for many decades. Source: Death rates: US Mortality Data, 1960-
2005, US Mortality Volumes, 1930-1959, National Center for Health Statistics, Centers 
for Disease Control and Prevention, 2006. Cigarette consumption: US Department of 
Agriculture, 1900-2007. Figure originally published in (Jemal, Bray et al. 2011). 
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Histological Classification and progression 
For the purposes of treatment there are two major forms of lung cancer are non–
small-cell lung cancer (NSCLC) (about 85% of all lung cancers) and small-cell lung 
cancer (SLC) (about 15%). Non–small-cell lung cancer can be divided into three major 
histologic subtypes: squamous-cell carcinoma, adenocarcinoma, and large-cell lung 
cancer. Smoking causes all types of lung cancer but is most strongly linked with small-
cell lung cancer and squamous-cell carcinoma; adenocarcinoma is the most common type 
in patients who have never smoked (Herbst, Heymach et al. 2008). Figure 2 shows the 
linear progression of squamous-cell carcinoma from normal epithelium to hyperplasia, 
squamous metaplasia, dysplasia, carcinoma in situ and finally to invasive carcinoma  
(Wistuba and Gazdar 2006). Similar to the adenocarcinoma sequence of colorectal 
cancer, lung adenocarcinoma is thought to follow a linear progression in which a 
precursor lesion progresses to adenocarcinoma in situ (Yatabe, Borczuk et al. 2011) as 
shown in Figure 3. 
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Figure 2.  Step wise histopathological and molecular changes during the 
pathogenesis of squamous cell carcinoma of the lung. Figure originally published in 
(Wistuba and Gazdar 2006). 
 
 
 
 
 
 
 
Figure 3.  Progression models of adenocarcinoma:  
The figure shows a comparison between current linear progression schema and novel 
non-linear progression scheme of lung adenocarcinoma. Current model follows a single 
linear progression regardless of the genes involved, whereas the novel model has several 
pathways to invasive adenocarcinoma, some of which may be terminated prior to 
invasive adenocarcinoma. Figure originally published in (Yatabe, Borczuk et al. 2011). 
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Genetic Risk Factors 
Not all cigarette smokers develop lung cancers. Currently, there is an attempt to 
identify the genetic factors that may contribute to the development of lung cancer. Lung-
cancer susceptibility and risk  are also increased in inherited cancer syndromes caused by 
rare germ-line mutations in p53 (Hwang, Cheng et al. 2003), retinoblastoma (Sanders, 
Jay et al. 1989) , and other genes (Bailey-Wilson, Amos et al. 2004) as well as a germ-
line mutation in the epidermal growth factor receptor (EGFR) gene (Bell, Gore et al. 
2005). More recently, three large genome-wide association studies identified an 
association between single-nucleotide polymorphism (SNP) variation of the long arm of 
the chromosome 15q24/15q25.1 and susceptibility to lung cancer. The region of the SNP 
variation was recently linked to lung carcinogenesis and includes two genes encoding 
subunits of the nicotinic acetylcholine receptor alpha, which is regulated by nicotine 
exposure (Lam, Girard et al. 2007; Amos, Wu et al. 2008; Hung, McKay et al. 2008; 
Thorgeirsson, Geller et al. 2008).  The three large genome-wide studies are appropriately 
replicated and provide a strong evidence for an association between SNP variation at 
15q24/15q25.1 and lung cancer. But they differ whether the connection is direct or 
mediated via smoking behavior.  
Lung-cancer susceptibility and risk also increase with reduced DNA repair 
capacity or increased expression of DNA synthesis and repair genes (Spitz, Wei et al. 
2003). Reduced DNA repair capacity from germ-line alterations in nucleotide excision 
repair genes such as ERCC1 in non-small cell lung cancer correlates with better 
prognosis (Yu, Zhang et al. 2008). Similarly, increased expression of DNA synthesis and 
repair genes, including RRM1 (the regulatory subunit of ribonucleotide reductase) in 
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non– small-cell lung cancer correlates with a better overall prognosis (Zheng, Chen et al. 
2007). Figure 4 below presents gene abnormalities involved in the development of 
different histologic types of lung cancer.  
 
Figure 4. Genetic abnormalities observed in lung cancer. Table originally published in 
(Herbst, Heymach et al. 2008). 
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Other Genetic Changes in Lung Cancer 
Microsatellite alterations 
Microsatellite repeats (also known as short tandem repeats) are highly 
polymorphic, widely distributed throughout the genome, and have been very useful 
markers for genetic mapping and analyzing small amounts of tumor samples for loss of 
heterozygosity (LOH).  There are a handful of publications that reported microsatellite 
alterations (MA) in lung cancer (Merlo, Mabry et al. 1994; Shridhar, Siegfried et al. 
1994; Adachi, Shiseki et al. 1995; Fong, Zimmerman et al. 1995; Ryberg, Lindstedt et al. 
1995; Chen, Stroun et al. 1996; Miozzo, Sozzi et al. 1996).  Overall, compiling the data 
from all the studies, 35% (37/106) of SCLCs and 22% (160/727) of NSCLCs have shown 
some examples of microsatellite alterations at individual loci. It also remains to be seen 
whether MA, observed in lung cancer plays a causative role resulting in disruption of 
specific genetic targets involved in carcinogenesis, or alternatively, reflects non-specific 
genome destabilization. Finally, it will be important to determine whether the detection of 
this defect and the resultant MA phenotype can be exploited for the early diagnosis of 
lung cancer. 
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Figure 5. Microsatellite alterations in lung cancer.  
Table originally published in (Sekido, Fong et al. 1998). 
Expression of Telomerase Activity 
All human chromosomes ends (telomeres) contain tandem tracks of the hexameric 
nucleotide repeat TTAGGG. During normal cell division, telomere shortening occurs due 
to the loss of telomeric repeats causing an `end replication problem'. This process of 
progressive telomere shortening leads to senescence and thus governing normal cell 
‗mortality‘. The length of terminal telomeric restriction fragments is altered in various 
type of tumors, including lung cancer. Telomere shortening was detected in 14 of 60 
primary lung cancers, while two cases showed telomere elongation (Hiyama, Ishioka et 
al. 1995).  About 100% of SCLC and 80-85% of NSCLC, were demonstrated to express 
high levels of telomerase activity potentially leading to cellular ‗immortality‘ (Kim, 
Piatyszek et al. 1994; Hiyama, Hiyama et al. 1995; Albanell, Lonardo et al. 1997).  
Functionally, high telomerase activity was associated with increased cell proliferation 
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rates and an advanced pathologic stage in primary NSCLCs (Albanell, Lonardo et al. 
1997).  There has been evidence that the telomerase is deregulated in the carcinoma in 
situ, indicating its involvement in early stages of development of lung cancer (Yashima, 
Litzky et al. 1997). 
Aberrant methylation in Lung Cancer 
DNA methylation involves covalent modification at the fifth carbon position of 
cytosine residues within CpG dinucleotides, which tend to be clustered in so-called CpG 
islands around the 5΄ ends of many genes. DNA methylation is necessary for proper 
embryonic development and appears to be associated with genetic repression. There are 
several possible theoretical ways by which methylation could affect gene expression. 
First, methylated CpG residues could interfere directly with the binding to specific 
transcription factors to DNA. Secondly, it can attract the repression factors to bind to the 
promoter, thus affecting gene expression. Thirdly, it can alter the chromatin structure and, 
thus repress the gene expression. In NSCLC, hypermethylation has been shown to 
specifically inactivate the p16INK4/CDKN2 gene (Merlo, Herman et al. 1995; Otterson, 
Khleif et al. 1995), whereas in SCLC, regional hypermethylation has been found at 
chromosome 3p, but the precise gene target is uncertain (Makos, Nelkin et al. 1992). In a 
large percentage of primary NSCLCs the expression of p16 protein is reduced but the 
frequency of somatic p16 mutations is considerably low. This observation suggests, p16 
is mostly inactivated by promoter hypermethylation. 
 
 
10 
 
Clonal Evolution 
Cancers evolve by a reiterative process of clonal expansion, genetic 
diversification and clonal selection within the adaptive landscapes of tissue ecosystems. 
Lung cancer is no exception to this rule. Changes in certain pro-inflammatory 
interleukin-8 (IL8) and some DNA-repair genes occur in nonmalignant lung tissue of 
smokers and patients with lung cancer, a finding consistent with diffuse tissue injury 
(Franklin, Gazdar et al. 1997; Spira, Beane et al. 2004; Spira, Beane et al. 2007). These 
changes probably precede epithelial clonal evolution. Patches of clonally related cells, or 
clonal patches containing 40,000 to 360,000 cells, have been mapped in the lung (Park, 
Wistuba et al. 1999). The size and number of subclones in a clonal patch are correlated to 
the progression of esophageal adenocarcinoma (Maley, Galipeau et al. 2006).  Some of 
the early events in the development of non small-cell lung cancer include loss of 
heterozygosity at chromosomal region 3p21.3 (site of RASSF1A, a member of the Ras 
association domain family, and FUS1), 3p14.2 (FHIT, a fragile histidine triad gene), 
9p21 (p16), and 17p13 (p53) (Wistuba, Mao et al. 2002).  Surprisingly, all these genes 
are tumor-suppressor genes. In lung cancer, the gatekeepers are inactivated first to let the 
disease progress. Several abnormalities have been observed in the normal tissue 
surrounding the non-small-cell lung tumors. They include clonal patches with  
methylation of promoter regions of genes (epigenetic changes), p53 mutation, EGFR 
mutation, c-Myc amplification, loss of heterozygosity and microsatellite instability (Park, 
Wistuba et al. 1999; Tang, Shigematsu et al. 2005; Sato, Shames et al. 2007). They may 
be at a greater risk of recurrence and a second primary tumor.  Recently, studies in mice 
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Figure 6. Molecular Evolution of Lung Cancer.  
Environmental factors, such as tobacco smoke, and genetic susceptibility interact to 
influence carcinogenesis. Factors unrelated to smoking, including genetic, hormonal, and 
viral (e.g., human papillomavirus) have been suggested (Sun, Schiller et al. 2007). Many 
molecular changes in the earliest-stage of cancer also occur in the advanced disease 
(Zudaire, Lozano et al. 2008). Premalignant patches contain clones and subclones (inset), 
which can involve loss of heterozygosity, microsatellite instability, and mutations (e.g., in 
p53 and epidermal growth factor receptor). Smoking-related patches and primary cancers, 
usually squamous-cell carcinoma and small-cell lung cancer, most often develop in the 
central airway (Wistuba, Berry et al. 2000). Most tumors that are not related to smoking 
are adenocarcinomas and develop in the peripheral airways. Figure originally published 
in (Herbst, Heymach et al. 2008). 
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have identified the existence of bronchoalveolar stem cells, which are considered to be 
the precursors of  lung adenocarcinomas (Kim, Jackson et al. 2005).  The pathways 
implicated in proliferation of these stem cells are KRAS, Pten, Phosphoinositide 3-kinase 
and cyclin dependent kinase (Yanagi, Kishimoto et al. 2007; Yang, Iwanaga et al. 2008). 
The role of these stem cells with regards to lung tumorigenesis and prognosis need to be 
investigated.  
Tobacco Smoking- the major cause of lung cancer 
Smoking is directly responsible for approximately 90% of the lung cancers and is also 
strongly associated with cancer of the head and neck, esophagus and urinary bladder.  
Smoking accounts for atleast 30%  of cancer deaths and is the single leading cause of 
cancer death in the United States. Figure 7 shows a the number of cancer related deaths 
attributed to smoking. 
 
Figure 7. Cancer related deaths attributed to smoking. Figure originally published in 
(Siegel, Naishadham et al. 2012). 
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Smoking-specific lung cancer death rates 
The lung cancer death rate increases exponentially with age in both current- and 
never-smokers. The absolute rates are 20-25 times higher among male smokers than 
never-smokers across most age groups, and 10-12 times higher in female smokers than 
never-smokers (Fig.8). As previously published in British Doctors'  (Pike and Doll 1965; 
Doll and Peto 1978) and US Veterans' (IARC, 1986), these are studies on the relationship 
between age, smoking status and lung cancer deaths.  As shown in Figure 8, the 
relationship between  age groups when both age and lung cancer death are plotted on a 
log scale appears linear across most age groups. The linear relationship, however doesnot 
hold true in the oldest smokers (men and women aged >85 years), perhaps reflecting the 
combined effect of lower lifetime smoking in the oldest birth cohort and less complete 
ascertainment of lung cancer as a cause of death in the elderly. 
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Figure 8. Lung cancer mortality by cigarette smoking status and age. Figure 
originally published in (Thun, Henley et al. 2002). 
Trends in lung cancer risk after smoking cessation 
For the first time, in its landmark publication, Peto et al.,2000 illustrated that the 
risk of lung cancer decreases when people stop smoking compared to those who continue 
to smoke.  This also serves as an important piece of the evidence for causality effect of 
smoking. It also indicates that continuing exposure affects even the late stages of 
carcinogenesis. Figure 9 depicts the relationship between age and the cumulative 
probability of death from lung cancer according to smoking status in CPS-II from 1984 ± 
91. In both men and women, the age-related increase in lung cancer risk is lowest in 
people who have never smoked, intermediate in those who have quit at various ages, and 
highest in current smokers. Among former smokers, the age-related increase is lower, the 
earlier the age of quitting. As seen in Figure 9, the cumulative probability of death from 
lung cancer continues to increase with age, even in never-smokers and former smokers.  
However, the increase in the probability of death is substantially slower than in current 
smokers. Studies that measure relative rather than absolute risk found that the relative 
risk of lung cancer approaches unity with time since cessation in former smokers, 
compared with those who have never smoked (US Department of Health and Human 
Services, 1990). The relative risk estimates fall below unity with time since cessation in 
former smokers compared to continuing smokers.  
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Figure 9.  Probability of death from lung cancer: Cancer Prevention Study-II men 
and women, 1984 ± 1991.  
It is based on nine rather than 6 years of follow-up to increase the statistical precision of 
the estimates, and excludes the first two years of follow-up (1982 ± 83) to avoid bias 
from smoking cessation due to tobacco-attributable disease. Figure originally published 
in (Thun, Henley et al. 2002). 
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Tobacco Carcinogens and Tobacco-Induced Lung Cancer 
The 2003 International Agency for Research on Cancer (IARC) monograph 
entitled ‗Tobacco Smoke and Involuntary Smoking‘, part of a review on the evaluation of 
carcinogenic risks to humans, came to the following conclusion regarding lung cancer on 
the basis of an extensive evaluation of the international literature (Hecht 2003). Cigarette 
smoking increases the risk of all histological types of lung cancer, including squamous -
cell carcinoma, small-cell carcinoma, adenocarcinoma (including bronchiolar/alveolar 
carcinoma) and large-cell carcinoma. It might seem obvious that carcinogens present in 
the tobacco cause the numerous cancers that are associated with the use of tobacco 
products, but in this age of cancer genes, protein complexes, cellular circuitry and signal-
transduction pathways, this simple fact is sometimes overlooked. Tobacco use is by far 
the most widespread link between exposure to known carcinogens and death from cancer, 
and is therefore a model for understanding mechanisms of cancer induction. 
Carcinogens in tobacco products 
Tobacco smoke is a heterogeneous mixture that contains approximately 4000 
chemical compounds. Figure 10 below summarizes our knowledge of carcinogens in 
tobacco products (Hoffmann, Adams et al. 1987; Hoffmann, Djordjevic et al. 1995; 
Swauger, Steichen et al. 2002).More than 60 known carcinogens have been detected in 
the smoke that is emitted at the mouth end of the cigarette during puffing also known as 
mainstream smoke and most of the same carcinogens are present in the smoke that is 
emitted from the burning cone between puffs, which comprises most environmental 
tobacco smoke also known as sidestream smoke. All of the carcinogens in Table3 have 
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been formally evaluated by the IARC. In each case, studies in either laboratory animals 
or humans have provided sufficient evidence of carcinogenicity. There are also likely to 
be other carcinogens that might be related to these, but have not been fully characterized 
or evaluated. There is a vast range of potencies and concentrations among these 
carcinogens. In general, strong carcinogens; the carcinogen that reproducibly produces 
tumors in laboratory animals after treatment with relatively low doses (typically 
micrograms or milligrams), such as polycyclic aromatic hydrocarbons (PAHs), 
nitrosamines and aromatic amines, occur in smaller amounts (1-200 ng per cigarette) than 
weak carcinogens that produce tumors in laboratory animals only after administration of 
relatively high doses such as acetaldehyde (nearly 1 mg per cigarette). The total amount 
of carcinogens in cigarette smoke adds up to 1-3 mg per cigarette (similar to the amount 
of nicotine, which is 0.5-1.5 mg per cigarette), although most of this consists of weaker 
carcinogenic agents such as acetaldehyde, catechol and isoprene (Hecht 2003). 
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Figure 10. List of carcinogens present in Tobacco smoke.  
Table originally published in (Hecht 2003).  
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Mechanism of Chemical Carcinogenesis 
When chemical carcinogens are internalized by cells, they are often metabolized. 
The initial step during conversion of organic xenobiotics into hydrophilic and excretable 
derivatives is mainly catalysed by CYP enzymes. CYP1A1 is the most important form in 
human lung. The resulting metabolic products are either excreted or retained by the cell. 
Inside the cell, carcinogens or their metabolic products can either directly or indirectly 
affect the regulation and expression of genes involved in cell-cycle control, DNA repair, 
cell differentiation or apoptosis. Some carcinogens act by genotoxic mechanisms, such as 
forming DNA adducts or inducing chromosome breakage, fusion, deletion, mis-
segregation, and non-disjunction. For example, carcinogenic ions or compounds of 
nickel, arsenic and cadmium can induce structural and numerical chromosome 
aberrations(Kawanishi, Hiraku et al. 2002; Kasprzak, Sunderman et al. 2003). Others act 
by non-genotoxic mechanisms such as induction of inflammation, immunosuppression, 
formation of reactive oxygen species, activation of receptors such as arylhydrocarbon 
receptor (AhR) or oestrogen receptor (ER), and epigenetic silencing. Together, these 
genotoxic and non-genotoxic mechanisms can alter signal-transduction pathways that 
finally result in hypermutability, genomic instability, loss of proliferation control, and 
resistance to apoptosis some of the characteristic features of cancer cells. A 
comprehensive picture of the genotoxic and non-genotoxic mechanisms induced by 
tobacco carcinogens is shown in Fig.11. 
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Figure 11.   An overview of genotoxic and non-genotoxic effects of carcinogens.  
Figure originally published in (Luch 2005). 
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Tumor promotion and tumor initiation by tobacco carcinogens 
Genotoxic carcinogens present in the cigarette smoke can induce damage in tumor 
suppressors or oncogenes in different ways, all of which contribute to the transformation 
of normal cells into tumor cells — this is known as the ‗tumor initiation‘ stage in 
carcinogenesis.  On the other hand, some chemical carcinogens  present in the cigarette 
smoke are also capable of promoting the outgrowth of those transformed cell clones and 
of contributing to the generation of visible tumor cell masses — this is known as the 
‗tumor promotion‘ stage in carcinogenesis (Fig. 12).  A large-scale series of experiments 
were undertaken to examine the promoting activity in cigarette smoke condensate by 
painting mouse skin which had been given a threshold dose of Benzopyrene.  The 
concentration of Benzopyrene was considered too low for complete carcinogenesis (Roe, 
Salaman et al. 1959). However, it was thought that it could act as an initiator, especially 
when with other PAHs in the condensate such as BA and DBA that are negative or 
borderline as carcinogens but are relatively potent initiators (Van Duuren, Sivak et al. 
1970). The factors shown in the figure below are only a few examples of a great number 
of factors that have been shown by gene-expression analysis to be altered following 
carcinogen exposure. In the figure below, binding of TCDD or BP to AhR leads to 
activation and translocation of the complex into the nucleus where it binds to xenobiotic-
responsive elements (XREs) and induces the expression of a variety of different genes 
involved in carcinogen metabolism, including CYP forms 1A1, 1B1 and 1A2. It also 
changes the expression pattern of several factors involved in cellular growth and 
differentiation, such as plasminogen-activator inhibitor type 1 (PAI1), metallothionein II 
(MT-II), human enhancer of filamentation 1 (HEF1), guanine nucleotide exchange factor 
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(GEF), COT and KRAS. Pro-apoptosis factors such as tumour-necrosis factor (TNF; 
superfamilies) and heat-shock protein 40 (HSP40) are downregulated, and cell-cycle 
genes can either be upregulated (such as cyclin B2) or downregulated (such as NEK2). 
COT and NEK2 are serine/threonine kinases (Luch 2005). 
 
 
 
 
 
 
 
Figure 12. Tumor promotion and Tumor initiation by the carcinogens 
a. Chemical compounds such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or 
benzopyrene (BP) result in tumor promotion through arylhydrocarbon receptor (AhR)-
mediated signal transduction. b. Tumor initiation occurs through DNA-adduct-derived 
mutations in cancer susceptibility genes. DNA binding by genotoxic carcinogens such as 
activated BP leads to the induction of base pair or frame shift mutations in cancer-
susceptibility genes such as TP53 or RAS. Figure originally published in (Luch 2005). 
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Co-carcinogens in Cigarette Smoke 
Although there is a large body of information on promoters and their mechanism of 
action, the promotional procedure of a single application of a PAH carcinogen followed 
by multiple applications of promoters. One problem to this approach is that when a 
person smokes the person does not consume one or two components; rather they are 
exposed to the many components of cigarette smoke. This approach does not correctly 
simulate the simultaneous, long-term exposure of smokers to the many components of 
cigarette smoke.  The much less studied procedures of co-carcinogenesis in which 
carcinogen and accessory substances are applied simultaneously over extended periods of 
time is a closer fit to the extended exposure of human smoking. Twenty-one compounds 
were tested for co-carcinogenic activity, 18 of which are found in cigarette smoke 
condensate (Van Duuren, Katz et al. 1973; Van Duuren and Goldschmidt 1976). Seven of 
the compounds were strong co-carcinogens that occur in cigarette smoke condensate 
(Van Duuren and Goldschmidt 1976) (Fig. 13). 
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Figure 13. Co-carcinogenesis by some representative constituents in cigarette smoke 
condensate. Table originally published in (Van Duuren and Goldschmidt 1976).  5µg BP 
was applied in the same solution as the co-carcinogen in 0.1 ml acetone three times 
weekly to the dorsal skin of 50 female Swiss mice for 368 or 440 days. Controls of BP or 
co-carcinogen alone in acetone, or acetone alone, were similarly applied. 
Mechanisms of Lung Carcinogenesis induced by smoking 
The central role of DNA adducts: From Figure 14 we can see that  carcinogens 
form the link between nicotine addiction and lung cancer, and DNA adducts are crucial in 
this process (Hecht 2003).  Other tobacco related cancer follow a similar schemes, they 
may only differ in specific details. Most carcinogens in tobacco products require 
metabolic activation before they are able to react with DNA, although some, such as 
ethylene oxide, formaldehyde and acetaldehyde, can react directly. Metabolic activation 
is generally initiated by cytochrome P450 enzymes (P450s), which are part of normal 
mammalian systems designed to respond to foreign compounds (Guengerich 2001). Most 
of the metabolites formed in these P450-catalysed reactions are excreted in a detoxified 
form or undergo further detoxification reactions, but some metabolites are electrophilic 
and react with DNA to form DNA adducts. There is convincing evidence for the presence 
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of adducts derived from these carcinogens in the DNA of human lung cells (Phillips 
2002). There is also ample literature about the metabolic activation pathways that lead to 
DNA-adduct formation, as well as the competing detoxification pathways that lead 
primarily to excretion. Cellular repair systems remove DNA adducts through various 
DNA repair mechanisms and return DNA structure to its normal state (Wei, Cheng et al. 
2000;Norbury and Hickson 2001; Goode, Ulrich et al. 2002). However, if the adducts 
persist and escape repair, mutations arise. It has been established conclusively that DNA 
adducts derived from cigarette-smoke carcinogens mainly Benzopyrene, cause miscoding 
most frequently in G-T and G-A mutations (Loechler, Green et al. 1984;Singer and 
Essigmann 1991; Seo, Jelinsky et al. 2000). If these permanent mutations occur in the 
crucial regions of the oncogenes (Ras and Myc), or in tumor-suppressor genes (p53 and 
CDKN2A (which encodes p16)), the result can be loss of normal cellular homeostasis 
and finally development of cancer (Osada and Takahashi 2002). Interference with the 
formation of DNA adducts results in decreased carcinogenicity (Adriaenssens, White et 
al. 1983; Hecht 1998; Kensler, Groopman et al. 1999; Boysen, Kenney et al. 2003). The 
central role of DNA adducts in carcinogenesis has been established and confirmed as 
biological fact over the past 50 years(Miller 1994). 
The effect of Nicotine: More recent studies indicate, however, that additional 
deleterious effects of nicotine and tobacco specific-nitrosamines such as NNK might be 
mediated through cell-surface receptors. Nicotine, NNK, and probably NNAL, bind to 
nicotinic-acetylcholine receptors and other receptors, leading to activation of the 
serine/threonine kinase AKT (also known as protein kinase B), protein kinase A and 
other factors (Schuller 2002; West, Brognard et al. 2003). This leads to biological effects 
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such as decreased apoptosis, increased formation of arachidonic-acid metabolites, 
increased cell proliferation and thus, neoplastic transformation. Nicotine also stimulates 
angiogenesis and tumor growth (Heeschen, Jang et al. 2001) through nicotinic-
acetylcholine receptors. The putative mechanism involves endothelial production of nitric 
oxide, prostacyclin and vascular endothelial growth factor. These data suggest that 
nicotine might have tumor-promoting or co-carcinogenic activity other than just 
contributing to addiction to cigarette smoking. However, mixed results have been 
obtained, depending on the animal model and study design used, with some studies 
showing evidence of co-carcinogenicity, whereas others showed no effect or inhibition by 
nicotine (Habs and Schmahl 1976; Gurkalo and Volfson 1982; Berger, Petru et al. 1987; 
Chen and Squier 1990).Carcinogenicity studies of nicotine have mostly been negative, 
except when nicotine was administered in the presence of hyperoxia, which caused some 
tumors in hamsters(Schuller, McGavin et al. 1995).  
Effect of Co-carcinogens and tumor promoters: Tobacco smoke also contains 
co-carcinogens and weakly acidic tumor promoters (Van Duuren, Katz et al. 1973; Hecht, 
Carmella et al. 1981) (Fig. 10). Although the mechanisms by which tobacco-smoke co-
carcinogens and tumor promoters enhance carcinogenesis are not clearly established, 
studies with other tumor promoters show that they can activate signaling by protein 
kinase C, activator protein 1 (AP1) and other factors(Dong, Birrer et al. 1994).  
Another emerging mechanism of gene silencing induced by tobacco 
carcinogenesis is by promoter hyper-methylation (Baylin, Herman et al. 1998).Recent 
studies show that inactivation of the CDKN2A tumor-suppressor gene and O6-
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methylguanine-DNA methyltransferase DNA-repair genes are common in non small-cell 
lung cancer(Palmisano, Divine et al. 2000). 
An additional requirement is that this process has to continue on an average of 50 
years. In other words, on an average a man develops lung cancer after smoking for 50 
pack years, which is one pack per day for 50 years. The resulting chronic DNA damage is 
consistent with the multiple genetic changes that are seen in lung and other tumors, as 
normal tissues progress from hyperplasia to dysplasia to carcinoma in situ to invasive 
cancer(Park, Wistuba et al. 1999; Osada and Takahashi 2002; Wistuba, Mao et al. 2002). 
 
Figure14.  Scheme linking nicotine addiction and lung cancer through tobacco-
smoke carcinogens.  
The events outlined in Figure must occur chronically for approximately 30-50 years for 
cancer to develop. Carcinogens are delivered with each puff of each cigarette every day 
during this time period. Figure originally published in (Hecht 2003). 
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The TGF-β pathway 
The TGF-β super-family of growth factors comprises seven genes in Drosophila 
melanogaster and at least 30 genes in mammals, including 3 TGF-β isoforms, 4 activin β
‑chains, the protein nodal, 10 bone morphogenetic proteins (BMPs) and 11 growth this 
receptor family, some of which may be shared by different TGF-β ligands. All these 
ligands are synthesized as dimeric pre-proproteins (Samanta and Datta 2012). 
Dimerization requires the pro-domains (Gray and Mason 1990; Shimmi, Umulis et al. 
2005) and therefore occurs intra-cellularly, before cleavage by proteases of the subtilisin 
like pro-protein convertase (SPC) family (Dubois, Laprise et al. 1995; Constam and 
Robertson 1999). The mature, fully processed dimeric growth factors are subsequently 
secreted. TGFβs are secreted as latent forms while still non-covalently attached to their 
pro-peptide. They require a further activation step to release the active ligand (Annes, 
Munger et al. 2003), which involves the metallo-protease BMP1 (also known as Tolloid 
in D. melanogaster) (Ge and Greenspan 2006). Ligands of the TGF-β superfamily of 
growth factors regulate many cellular functions including cell growth, adhesion, 
migration, cell-fate determination and differentiation, and apoptosis. Malfunctions in 
signaling downstream of TGF-β are implicated in serious human diseases such as cancer, 
fibrosis, wound-healing disorders, and several hereditary conditions such as familial 
primary pulmonary hypertension and hereditary Haemorrhagic Telangiectasia (HHT). 
The growth inhibitory effect of TGF-β signaling in epithelial cells explains its role as a 
tumor suppressor in carcinomas, although TGF-β expression by tumor cells contributes to 
cancer progression as well. Signaling primarily occurs through Smad protein dependent 
pathways whereby ligand binding to TBRII induces phosphorylation and activation of 
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TGF-β type I receptor (TβRI). After interaction with TβRI, phosphorylated Smad2 and 
Smad3 dissociate to form a heterotrimeric complex with Smad4 and translocate into the 
nucleus to regulate gene transcription (Fig. 15). TGF-β signaling may also proceed via 
less well-understood SMAD independent pathways. These ―noncanonical‖ pathways 
involve various signaling cascades including Ras/ERK, Rho/ROCK, and TAK1/MAPK 
and are likely to have important roles in mediating the pro-tumorigenic effects of 
TGFβ(Massague 2000). Depending on context, TGF-β signaling may alternatively 
function to suppress tumor growth or to promote tumor cell invasion and metastasis. 
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Figure15.  Alterations of the Smad dependent TGF-β pathways in Cancer.   
The components that are mutated, deleted or down-regulated, are shown in green, while 
the components that are amplified or over-expressed, are shown in red. Figure originally 
published in (Samanta and Datta 2012). 
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Lung cancer and TGF-β 
Although most lung cancer cells secrete TGF-β, the malignant transformation in lung 
cancer results in a loss of the tumor suppressor effects of TGF-β. Loss of  TGF-β 
response, which results in loss of inhibitory effect of TGF-β on proliferation, has been 
associated with tumor development and or tumor progression in several cancers(Kim, Im 
et al. 2000).  Reduced expression and inactivation of TGF-β receptors were associated 
with loss of sensitivity with anti-proliferative effects of TGF-β in carcinogenesis(de 
Caestecker, Piek et al. 2000). The unresponsiveness to TGF-β could be caused by 
multiple ways involving both genetic and epigenetic alterations of TGF-β type II receptor 
expression (TβRII)(Osada, Tatematsu et al. 2001). Mutations within the coding sequence 
of the TβRII gene are rare in non–small cell lung cancer (NSCLC).  Mutations in Smad2 
and Smad4 genes have been found in 5-10% of lung cancers (Nagatake, Takagi et al. 
1996; Uchida, Nagatake et al. 1996). It was shown that 29 of 33 lung cancer cell lines are 
unresponsive to TGF-β–induced growth inhibition (Hougaard, Norgaard et al. 1999). 
TβRII expression was shown to be decreased in 80% of squamous cell carcinoma, 42% 
adenocarcinoma, and 71% large cell carcinoma (Anumanthan, Halder et al. 2005). Study 
from our lab had shown that the stable expression of TβRII in TGF-β–unresponsive cells 
restores TGF-β–induced inhibition of cell proliferation, induction in apoptosis, and 
decrease in tumorigenicity(Anumanthan, Halder et al. 2005). The loss of TGFβRII not 
only contributes to tumorigenesis but also contributes to metastasis. In a recent study, 
researchers have identified a transcriptional profile that distinguishes invasive from 
noninvasive lung adenocarcinoma, this includes reduced expression of a previously 
identified tumor suppressor, TGFβRII, and suggests that down regulation is an early step 
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in adenocarcinoma metastasis. Potential mediators of invasion resulting from suppression 
of TGFβRII in tumors were identified and include several transcriptional factors and E-
cadherin, which were lower in TGFRII knock-down cells and in primary invasive tumor 
specimens(Borczuk, Kim et al. 2005). However, there is a conflicting observation that in 
lung cancer, overexpression of TGF-β is associated with better prognosis in 5-year 
patient survival (Inoue, Ishida et al. 1995). TGFβ-1 level in serum was elevated after 
radiotherapy in lung cancer, and the risk of radiation induced lung injury is associated 
with TGF-β1 single nucleotide polymorphism(Yuan, Liao et al. 2009; Zhao, Wang et al. 
2009). Additional complexity for the involvement of the TGF-β pathway is provided by 
the feedback loop exhibited by the inhibitory Smads namely, Smad6 and Smad7. In a 
recently publication (Jeon, Dracheva et al. 2008) observed that in lung cancer, Smad6 is 
overexpressed in a portion of the tumors, and high expression of Smad6 is associated 
with poor survival in patients with non-small cell lung cancer. Knockdown of Smad6 in 
overexpressed lung cancer cells induced apoptosis and growth arrest at the G1 phase, 
which contributed to the reestablishment of TGF-β homeostasis in lung cancer cells by 
reactivating the TGF-β signal pathway(Jeon, Dracheva et al. 2008). This study indicates 
that I-Smads play a critical role in tumorigenesis by regulating TGF-β homeostasis in 
normal and cancer cells. Given the causal role of smoking in inducing lung cancer, there 
has been no report that smoking effects the TGF-β signaling in the context of lung cancer 
or infact in any cancer.  So we wanted to pursue the effect of long-term smoking on TGF-
β signaling and what effect does it have with regards to lung tumorigenesis and lung 
cancer therapy. 
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Aims of Dissertation 
The aims of the dissertation were: 
1. To evaluate the role of long-term smoking on Smad dependent TGF-β 
signaling and its contribution to lung tumorigenesis in NSCLC. 
Epidemiological studies have demonstrated that most cases of lung cancers (85-
90%) are directly attributable to cigarette smoking. Although much information 
has been gained about the effects of cigarette smoking on various signaling 
pathways causing lung cancer, nothing is known about the effect cigarette 
smoking on the TGF-β-induced tumor suppressor function in lung cancer. To 
address this issue, lung adenocarcinoma A549 and immortalized bronchial 
epithelial HPL1A cells were chronically treated with cigarette smoke condensate 
(CSC) and Dimethyl sulphoxide (DMSO, as a control) to mimic the conditions of 
long-term cigarette smoking. A possible role for long-term smoking in decreasing 
Smad3 expression; abrogating TGF-β mediated growth inhibition and thus its 
contribution to lung tumorigenesis was identified. 
 
2. To evaluate the role of long-term smoking mediated decrease in Smad3 to 
resistance in Carboplatin based chemotherapy in NSCLC.  
While numerous cell-signaling pathways are known to play decisive roles in 
chemotherapeutic response, relatively little is known about the impact of the 
Smad dependent TGF-β pathway on therapeutic outcome. Previous reports 
suggested that lung cancer patients who continue to smoke while receiving 
chemotherapy have poorer outcome than their nonsmoking counterparts. In our 
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previous study, we showed that long-term CSC mediated downregulation of 
Smad3 induces tumorigenesis.  The objective of this study was to study identify 
the role of Smad3 in chemoresistance induced by cigarette smoke condensate 
(CSC) in human lung cancer cell lines namely, A549 and HPL1A. 
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CHAPTER II 
Materials and Methods 
Cell lines and Cell Culture 
Human lung adenocarcinoma cells (A549) obtained from ATCC and human lung 
immortalized epithelial cells (HPL1A) (a kind gift of Dr. T. Takahashi), Mycoplasma 
negative by a PCR detection method (4/10/10 and 10/08/10 testing Sigma Venor-Gem); 
were maintained in RPMI with 10% FBS supplemented with penicillin/streptomycin and 
L-glutamate. All cell lines were cultured and maintained at 37ºC in a humidified 
incubator in the presence of 5% CO2. Cells were treated with CSC at 25µg/ml or with the 
same volume of DMSO as controls for 4,100 and 300 days Mycoplasma negative by a 
PCR detection method (4/10/10 and 10/08/10 testing Sigma Venor-Gem). Both A549 and 
HPL1A were obtained during 2006, were tested and authenticated by DNA profiling for 
polymorphic short tandem repeat (STR) markers at Vanderbilt University DNA 
Sequencing & Analysis Core most recently in April 2011. 
Reagents and antibodies 
CSC was purchased from Murty Pharmaceuticals, Inc. It was prepared from the 
University of Kentucky‘s 3R4F cigarettes. G-Sepharose beads were purchased from 
Sigma Bio chemicals (St. Louis, MO). TGF-β1 was purchased from R&D Systems 
(Minneapolis, MN). The anti-β-actin antibody, Bcl-2 siRNAs, N-ter was purchased from 
Sigma Biochemicals (St. Louis, MO). Rabbit anti-Smad2 and anti-Smad3 were from 
Zymed Laboratories, Inc. (San Francisco, CA). Mouse anti-Smad3, anti-Smad4 and anti-
Bcl-2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phospho-
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Smad2, Bax, Bcl-xl, and Bcl-w antibodies were purchased from Cell Signaling 
Technology (Beverly, MA). MTT kit and ChIP assay kits were purchased from Millipore 
(Temecula, CA). 
Immunoprecipitation and Immunoblot Analyses 
For immunoprecipitation, cells were serum-starved for 2 hours and treated with 
12.5ng/ml TGF-β1 for 1 hour and cell lysates were made.  4, 100 and 300-days of CSC 
treated A549 and HPL1A cells were serum-starved for 2 hours and treated with 12.5 
ng/ml TGF-β1 for 1 hour. Cells were solubilized in lysis buffer. An equal amount of each 
protein lysate was incubated with both anti-Smad2 and anti-Smad3 polyclonal antibodies 
for 2 hours at 4°C, followed by incubation with 20 µl of protein G-Sepharose beads for 1 
hour. The immune complexes were analyzed by Western blot analyses with mouse anti-
Smad4 antibody. Protein lysates were also subjected to Western blot analyses with anti-
phospho-Smad2, anti-Smad2, anti-Smad3, anti-Smad4 and mouse anti-β-actin antibodies. 
Transcriptional response assay 
Cells were transiently transfected with either p-3TP-Lux, (CAGA)9-MLP-Luc or 
Smad3 plasmids and with CMV-β-gal plasmid as an internal control for transfection 
efficiency. .  The Smad3 Luc-reporter plasmid containing  1,892-bp fragment 
corresponding to -1879 to +13 relative to the ATG start site of the human gene Smad3 
cloned upstream of the luciferase-reporter gene was a generous gift of  Dr. Thomas J. 
Kelly (Department of Pediatrics, Case Western Reserve University, Cleveland, US).   For 
the experiments with p-3TP-Lux, (CAGA)9-MLP-Luc, transfected cells were incubated 
in 0.2% FBS with 5 ng/ml TGF-β1 for 22 hours.  For experiments with the Smad3 
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promoter they were not treated with TGF-β1. Cell lysates were used to measure both 
luciferase and β-gal activities, and the normalized luciferase activity was presented. 
Quantitative Real Time PCR 
Total RNA was isolated from cells by extraction of RNA by using Trizol reagent 
(Invitrogen) and alcohol precipitation. The results would be quantitated by 2^(-ΔΔCt) 
method where ΔΔCt = ΔCt,CSC-ΔCt,DMSO . Here, ΔCT, CSC is the Ct value for Smad3 
normalized to the GAPDH in 300 day CSC treated cells and ΔCt, DMSO is the Ct value 
for the Smad3 also normalized to GAPDH in 300 days DMSO treated cells. Fold changes 
were calculated in paired samples of CSC and DMSO treated for various time points 
using the Sybr green real-time PCR method and the Applied Bio systems 7700 Sequence, 
Detection System. Reaction conditions were 95°C for 10 sec, 58°C for 45 sec, (45 
cycles). 
Primers and probes used for RT-PCR were as follows: 
Smad3 Forward: 5‘- CCA GAA CCA AAC CTC AAC AC-3‘ 
Smad3 Reverse: 5‘- TCCTCTTGCGTACGTTTTTC-3‘ 
GAPDH Forward: 5‘- GCCTCAAGATCATCAGCAATG-3‘ 
GAPDH Reverse: 5‘- CTTCCACGATACCAAAGTTGTC-3‘ 
Cell Viability Assay 
Cell viability was measured with the MTT assay according to manufacturer‘s 
recommendations. Cells in the exponential phase were dispensed in 96-well plates 
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overnight at a density of 2×10
3 
cells per well. Cells were then treated with TGF-β 
(5ng/ml) for a total of 5 days. TGF-β containing media was replaced every other day. The 
optical density was transformed to cell numbers by a standardization curve done 
simultaneously. 
Cell Death ELISA 
Various time points of CSC and corresponding control cells (20,000 per well) 
were seeded into 12-well plates and allowed to attach for 20 hours. Cells were serum 
starved for 72 hours. Cells (floating and adherent) were lysed in 200 µl of lysis buffer. 
Each lysate (10 µl) was used for ELISA (Roche Molecular Biochemicals, Indianapolis, 
IN). 
Bcl2 siRNA knockdown 
20nM of Bcl2 siRNAs (Sigma Aldrich) were transiently transfected into 300-days 
CSC treated A549 and HPL1A cells using N-ter a transfection reagent (Sigma Aldrich) 
according to the manufacturer's instructions. A control siRNA (nonhomologous to any 
known gene sequence) and transfection just with the transfection reagent N-ter were used 
as negative controls. The concentration was determined from the initial experiments 
optimizing the concentration for the minimum concentration of siRNA required to 
knockdown Bcl2 more than 80%. The level of Bcl2 expression was determined by 
Western blot using a Bcl2 antibody, 72 hours after transfection. Three independent 
experiments were conducted to determine specific silencing of the targeted Bcl2 gene.  
Bcl2 siRNAs sequences are available upon request. 
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Apoptosis by Flow cytometry 
The cells were transfected with Bcl2 siRNAs and then the cells were serum 
starved for 72 hours and assayed for apoptosis. The cells were harvested, washed with 
cold PBS, and cells were stained with PI and Annexin-V-FITC using ANNEXIN V-
FITC/PI Kit (BD Biosciences) for apoptosis analysis according to the manufacturer‘s 
protocol. Stained cells were immediately analyzed by fluorescence activated cell sorting 
(FACS; Cell Lab Quanta SC; Beckman Coulter).  
Chromatin Immunoprecipitation Assay 
Chromatin immunoprecipitation assay (ChIP) assays were performed via a 
commercially purchased chromatin immunoprecipitation kit (Millipore, Temecula, CA), 
using either anti-Sp1 (Santa Cruz Biotechnology, Santa Cruz, CA; pep-2) or anti-HDAC1 
(Millipore; 17-608), antibodies. Cells were first cross-linked for 10 min by adding 
formaldehyde directly to tissue culture medium to a final concentration of 1%. Cross-
linked cells were then washed twice with cold PBS (with protease inhibitors), scraped, 
pelleted, resuspended in 200 μl SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris-
HCl, pH 8.0), and incubated for 10 min on ice. The lysates were then sonicated for five 
cycles of 30 s each, resting on ice for 1 min between cycles. After sonication, the samples 
were centrifuged and the supernatants diluted 10-fold in ChIP dilution buffer with 
protease inhibitors and precleared with 60 μl salmon sperm DNA/protein A Agarose-50% 
slurry for 60 min at 4°C. Cross-linked chromatin was incubated overnight with 5 μg Sp1, 
4 μl HDAC1, or control IgG in a total volume of 1 ml at 4°C. Antibody-protein-DNA 
complexes were isolated by immunoprecipitation with 60 μl salmon sperm DNA/protein 
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A. After extensive washing, pellets were eluted by freshly prepared elution buffer (1% 
SDS, 0.1 M NaHCO3). Formaldehyde cross-linking was reversed by 5-12-h incubation at 
65°C after adding 20 μl 5 M NaCl. Samples were purified through PCR purification kit 
columns (Qiagen, Chatsworth, CA) and used as a template in PCR. ChIP primers:  
5′-CGAGGGGGCGGTGACAGCA-3′ and  
5′-CCTCGCTAGCTTTGATGCGCAGA- 3′ were used to amplify a 200-base pair 
fragment corresponding to the core Smad3 promoter. Samples from at least three 
independent immunoprecipitations were analyzed.  
Stable Overexpression of Smad3 in 300-day CSC treated cells 
300-day CSC treated A549 cells were stably transfected with Smad3-pCDNA3 or 
pCDNA3 vector. Transfected cells were selected for two weeks in presence of G418, 
400μg/ml for 300-day A549, and 200μg/ml for 300-day HPL1A cells. Polyclonal 
population cells were used to isolate clones and the expression of Smad3 in each clone 
was verified by immunoblot analysis using Smad3 antibody. Clones that expressed a 
higher level of Smad3 were selected for experiments and maintained in RPMI containing 
10% FBS in the presence of 300μg/ml for A549 and 150μg/ml for HPL1A cells. 
Stable Overexpression of Bcl2 in A549 and HPL1A cells 
A549 and HPL1A cells were stably transfected with Bcl2-pCDNA3 or pCDNA3 
vector. Transfected cells were selected for two weeks in presence of G418, 600 μg/ml for 
A549, and 400 μg/ml for HPL1A cells. Polyclonal population cells were used to isolate 
clones and the expression of Bcl2 in each clone was verified by immunoblot analysis 
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using Bcl2 antibody. Clones that expressed a higher level of Bcl2 were selected for 
experiments and maintained in RPMI containing 10% FBS in the presence of 300 μg/ml 
for A549 and 200 μg/ml for HPL1A cells. 
Smad3 siRNA knockdown in Bcl2 overexpression clones 
20 nM of Smad3 siRNAs (Sigma Aldrich) were transiently transfected into A549, 
HPL1A Bcl2 overexpressing clones using N-ter, a transfection reagent (Sigma Aldrich), 
according to the manufacturer's instructions. A control siRNA (nonhomologous to any 
known gene sequence) and transfection just with the transfection reagent N-ter were used 
as negative controls. The concentration was determined from the initial experiments 
optimizing the concentration for the minimum concentration of siRNA required to 
knockdown Bcl2, Smad3 more than 80%. The level of Smad3 expression was determined 
by Western blot using Smad3 antibody, 72 hours after transfection. Three independent 
experiments were conducted to determine specific silencing of the targeted Bcl2, Smad3 
genes. Smad3 siRNAs sequences are available upon request.  
MTT Assay 
In a 96-well flat-bottomed plate, 2000 cells/100 μl of cell suspension were used to 
seed each well. The cells were incubated overnight to allow for cell attachment and 
recovery. Cells were treated with indicated drugs and incubated for 72 hours at 37°C. 
After treatment, 10 μl of a 5 mg/ml solution in PBS of the 3-(4,5- dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) tetrazolium substrate (Millipore, Billerica, MA) 
was added to each well and incubated for ∼4 hours at 37°C. The resulting violet 
formazan precipitate was solubilized by the addition of 100 μl of a 0.04 M HCl in 
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Isopropanol solution. The plates were then analyzed on a microplate reader (MRX; 
Dynex Technologies, West Sussex, United Kingdom) at 570 nm and 630 (background) to 
determine the absorbance of the samples. 
Cell cycle Analysis 
Cells were plated at 1 × 10
6
/10 cm dish and allowed to grow overnight, and 
subsequently treated with carboplatin (70 µM) for 48 hours. Single-cell suspensions were 
labeled with 50 μg/ml propidium iodide (Sigma), and approximately 106 cells in 1 ml 
were analyzed by flow cytometry. Ten thousand cells were evaluated, and the percentage 
of cells in the G2 phase was denoted by the 2N population phase, which was determined 
using FlowJo Software. 
Tissue Samples and Tissue Microarrays 
Unstained tissue sections from tissue microarrays were obtained from the 
Vanderbilt Lung SPORE. They consist of Paraffin-embedded formalin-fixed tissues 
obtained from the archives of the pathology department at Vanderbilt University and the 
Department of Veterans Affairs Medical Center (VAMC, Nashville, TN). The study was 
approved by the local Institutional Review Boards for all institutions involved. Tissue 
microarrays of NSCLCs were prepared from paraffin blocks following the methods 
described by Kononen and colleagues and reported earlier. There are 42 tumors 
represented on the arrays. Hematoxylin and eosin (H&E) stained sections from all tissue 
blocks were reviewed by a pathologist with expertise in lung cancer (AG).  
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DNA Laddering 
Cells were serum-starved for 72 hours. Cells (floating and adherent) were 
collected and lysed. RNase A (5 µg/ml) was added to the clear lysate and incubated at 
56°C for 2 hours. Proteinase K (200 µg/ml) was then added and incubated at 50°C for an 
additional 2 hours. Treated samples were extracted twice with TE-saturated 
phenol/chloroform. DNA was precipitated with cold ethanol, washed, suspended in 20 µl 
of TE buffer, and analyzed by agarose gel electrophoresis. 
Soft agar assay 
To test the effects of smoking on anchorage-independent growth, vector controls 
and three stable Smad3 clones were compared for clonogenic potential in semi-solid 
medium. 10
3
 to 10
5
 cells from each pool were suspended in 1 ml of 0.4% in sea plaque 
agarose containing 10% FBS medium and then plated on the top of 1 ml of semi-
solidified 0.8% agarose in the same medium in 35-mm plates. Plates were incubated for 
17 days at 37˚C in the presence of 5% CO2 in a humidified incubator. Colonies grown on 
soft agarose were counted by automated colony counter and pictures of colonies were 
taken under the inverted microscope.   
Xenograft assay 
 Cells were assayed for tumorigenicity in 7-week-old athymic nude mice. 1X10
6
 
cells were injected subcutaneously behind the anterior fore limb of each mouse as 
indicated. The animals were monitored for tumor formation twice a week. Tumors were 
measured by slide calipers and tumor volume was calculated by the equation: V = L XW
2
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X 0.5, where V = volume, L = length, and W = width. Growth curves for tumors were 
plotted from the mean volume +/- SD of tumors from six mice. 
Immunohistochemistry 
Immunohistochemistry was performed as described in (19) with mouse 
monoclonal Smad3 incubated for 2 hours (dilution 1:100). Smad3 expression was 
evaluated semi quantitatively based on the intensity of staining and was scored as weak 
(+1), moderate (+2), and intense (+3). Samples with no staining were considered 
negative, and samples with weak-to-intense staining were considered positive.  
Public Database analysis for expression of Smad3 
We analyzed raw microarray data files from published NSCLC cohort microarray 
databases to assess the expression of the Smad3 in clinical samples of NSCLC. We used 
361 adenocarcinomas from a recent multi-site blinded validation study by the Director‘s 
Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma (22) 
that were initially surgically resected in Memorial Sloan Kettering (n=104), University of 
Michigan (n=178), and H. Lee Moffitt cancer center (n=79) (National Cancer Institute 
Cancer Array database, experiment ID 1015945236141280:1 
(https://caarraydb.nci.nih.gov/caarray). We excluded adenocarcinomas from the Dana 
Farber institute within the same report because of their reduced total gene expression 
levels as well as samples that were excluded in their original report.  All NSCLC samples 
analyzed included only those that passed the quality checks in the original published 
reports of the mentioned cohorts. In addition, each gene expression sample analyzed 
represents one unique patient. All raw data files were imported and analyzed using the 
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BRB-ArrayTools v.3.7.0 Beta Genes were normalized independently by cohort. Common 
genes present in all gene chip platforms (Affymetrix® HG-U133A, HG-U133 plus 2.0, 
and U95A) were identified using NetAffxTM 
http://www.affymetrix.com/analysis/index.affx. Kaplan-Meier and log-rank test survival 
analyses based on Smad3 expression were performed using the R 2.6.0 statistical package 
(http://www.r-project.org/). Expression of Smad3 was analyzed in the aforementioned 
cohort. Z-scores were calculated and plotted using Graph Pad Prism Software and Log-
rank statistics were then performed as described earlier to measure the survival 
differences among the identified patients.  
Statistical Analysis 
Descriptive statistics including mean values and SD were calculated using Prism 
software (Graph pad, La Jolla, CA). All data are representative of at least three 
independent experiments and are expressed as the means ± SD unless otherwise 
indicated. ANOVA was used to assess the differences between experimental groups, and 
survival curves, unless otherwise indicated.  
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CHAPTER III 
Introduction 
Cigarette smoking is the main risk factor for lung cancer, accounting for 90% of 
cases in men and 70-85% of cases in women. Approximately 1.3 billion people smoke 
cigarettes worldwide, which contributes to 5 million preventable deaths per year 
(Schembri, Sridhar et al. 2009). The vast majority of lung cancers are strongly correlated 
with tobacco consumption, and smoking cessation remains the only known way of 
reducing cancer risk in smokers (Thomson, Fisher et al. 2004). Cigarette smoking has 
been found to induce a number of genetic and molecular changes in the respiratory tract, 
including cellular atypia, loss of heterozygosity (Powell, Klares et al. 1999), and 
promoter hyper methylation (Guo, House et al. 2004). Microarray studies of bronchial 
epithelial cells have indicated that cigarette smoke induces, primarily, the expression of 
xenobiotic‐metabolizing and redox‐regulating genes but also point to the effects on tumor 
suppressor genes, oncogenes, and genes involved in the regulation of inflammation 
(Spira, Beane et al. 2004). Systematic analysis of mRNA and protein expression levels 
among thousands of genes has also contributed to defining the molecular network of lung 
carcinogenesis. Despite the fact that enormous progress in the understanding the 
molecular mechanisms leading to lung cancer has been made, how intrinsic Smad-
dependent TGF-β signaling is affected by smoking has not yet been investigated. 
Alterations in TGF-β signaling are linked to a variety of human diseases including 
cancer, inflammation and tissue fibrosis (Blobe, Schiemann et al. 2000; de Caestecker, 
Piek et al. 2000). The disruption of TGF-β signaling occurs in several human cancers and 
the pathway generally possesses a tumor suppressor function (Kato, Habas et al. 2002). 
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However, in the later stages of carcinogenesis the tumor cells become resistant to TGF-β-
induced growth arrest. Although alterations in TGF-β receptors have been implicated in 
the resistance to its tumor suppressor function, tumors may use various mechanisms 
anywhere along its primary cytoplasmic signal transducers, the Smad proteins, to 
circumvent the growth inhibitory effects of TGF-β (Bierie and Moses 2006; Levy and 
Hill 2006).  
The majority of the studies performed thus far were analyzed on short-term 
((Jorgensen, Dozmorov et al. 2004; Narayan, Jaiswal et al. 2004; Lemjabbar-Alaoui, 
Dasari et al. 2006) or long-term (Liu, Killian et al. 2010) exposure of epithelial cells to 
high doses of tobacco constituents. Interestingly, despite the fact that cigarette 
carcinogens mediate inactivation of numerous tumor suppressor genes, the relevance of 
cigarette smoking as to the overall prognosis of lung cancer patients remains 
controversial (Zhou, Heist et al. 2006; Itaya, Yamaoto et al. 2007). The present study was 
undertaken to ascertain if cigarette smoke induces any alterations in the Smad-dependent 
TGF-β signaling, which directly enhance the malignant phenotype of lung cancer cells. 
Here, we describe the results of a study in which immortalized human bronchial 
epithelial cells, HPL1A and lung adenocarcinoma cell line A549, were chronically 
exposed to low doses of cigarette smoke condensate (CSC) for approximately one year. 
Therefore, we intended to mimic, in vitro, the long-term exposure of human lung 
epithelium to smoke. We found that cells exposed to smoke for a long-term makes them 
tumorigenic or more tumorigenic by decreasing the levels of tumor suppressor protein 
Smad3. 
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Results 
Cigarette Smoke Condensate (CSC) treatment inhibits Smad-dependent TGF‐β 
signaling through down-regulation of Smad3 
To test the effect of CSC on TGF‐ β signaling, we looked at the functional 
complex formation between Smad2 or Smad3 and Smad4 by immunoprecipitation (IP) 
assays. A549 and HPL1A cells were treated with CSC (25 μg/ml) for 4, 100 and 300 days 
together with and without TGF‐ β for 1 hour. Lysates were subjected to IP with either 
anti-Smad2 or anti-Smad3 antibody followed by immunoblotting with anti-Smad4 
antibody. We observed that TGF-β-induced Smad3-Smad4 but not Smad2-Smad4 
complex formation was significantly reduced in chronically CSC treated cells for 300 
days, suggesting a biased role of CSC in blocking the Smad3-Smad4 complex formation 
in both the cell lines. The reduced Smad3-Smad4 complex formation in the long‐term 
CSC treated cells (300 days) was due to reduced levels of Smad3. There was no change 
observed in the levels of Smad2 or Smad4 (Fig. 16 A). We observed same results when 
we performed the reverse experiment, namely IP with anti- Smad4 and immunoblotted 
for Smad3 (Fig. 16 B). We observed the complex formation between Smad2,3 and 
Smad4  going down even when the lysates were prepared similarly as above  and were 
subjected to IP with both anti -Smad2 and anti - Smad3 together (Fig. 16C). 
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 Figure16.  Long-term CSC treatment abrogates Smad2/3-Smad4 complex 
formation by decreasing Smad3. 
A. Cell lysates from the different time points of CSC treatment were serum starved 
overnight and treated with TGF-β1 for 1 hour and were subjected to immunoprecipitation 
separately with anti-Smad2 and with anti-Smad3; antibodies and the immunoprecipitates 
were analyzed by Immunoblot analysis with anti-Smad4 antibody (top). Cell lysates were 
subjected to Immunoblot analysis with anti-Smad2, anti-Smad3 and anti-Smad4 with 
anti-β-actin acting as a loading control. 
B. Cell lysates at same condition were now subjected to immunoprecipitation with anti-
Smad4 antibody and the immunoprecipitates were analyzed by immunoblot analysis with 
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anti-Smad3 antibody.  Lower panels showing the expression Smad3 and Smad4 by 
Western Blot analysis. 
C.  Cell lysates from the same conditions were subjected to immunoprecipitation with 
anti-Smad2 and anti-Smad3; antibodies and the immunoprecipitates were analyzed by 
Immunoblot analysis with anti-Smad4 antibody (top). Cell lysates were subjected to 
Immunoblot analysis with anti-phospho Smad2, anti-Smad2, anti-Smad3 and anti-Smad4 
with anti-β-actin acting as a loading control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A 
B 
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Figure17. Long-term CSC treatment decreases TGF-β signaling. 
Reporter assay: CSC treated A549 and HPL1A cells were transiently transfected with 
CMV-β-gal and (CAGA) 9-MLP-Luc (A) and p3TP-Lux (B) reporter plasmids. 
Luciferase activity was normalized to β-gal activity, and the relative luciferase activity 
was expressed. Long term CSC treatment significantly reduced the TGF-β inducibility of 
the reporters (* p< 0.001) in both cell lines. 
 
 
 
 
 
 
To test whether the inhibition of Smad complex formation affects downstream 
transcriptional responses mediated by TGF‐β, we performed transient transfection assays 
using TGF‐β-responsive reporters, p3TP‐Lux and (CAGA)9‐MLP‐Luc. Both the reporters 
(CAGA)9‐MLP‐Luc (Fig. 17A) and  p3TP‐Lux (Fig. 17B) activities were reduced 
dramatically in 300-day CSC treated cells. Taken together these results suggest that the 
long-term CSC treatment decreases the Smad3-Smad4 complex formation due to a 
decrease in Smad3 expression and inhibits TGF-β-induced gene regulation. 
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CSC treatment decreases Smad3 mRNA, and the promoter activity and the 
expression is correlated to Histone Deacetylation 
To determine whether the Smad3 mRNA levels correlate with the protein levels 
we performed quantitative real-time PCR in the various time points of CSC treated cells 
along with the controls. We observed that the Smad3 mRNA goes down in the 300-days 
CSC treated cells compared to the control cells (300-days DMSO) (Fig. 18A) in both the 
cell lines. To determine whether the reduction in Smad3 expression by CSC is at the 
promoter level or due to post‐transcriptional changes, we transiently transfected Smad3 
promoter reporter (‐1878/+13) in both HPL1A and A549 cells pre‐treated with CSC for 4, 
100 and 300 days. Smad3 promoter activity was decreased by CSC in a time dependent 
manner (Fig. 18B). The Smad3 expression can go down through several epigenetic 
mechanisms namely histone deacetylation and DNA methylation. To test which 
epigenetic change, histone deacetylation or the DNA methylation, is playing a role in 
CSC‐induced down-regulation of Smad3, 300-day CSC treated A549 and HPL1A cells 
were treated with either HDAC inhibitor, Sodium Butyrate TSA or the methylation 
inhibitor, Azacytidine. Treatment of Sodium Butyrate (Fig. 18C) suppressed CSC‐
mediated down-regulation of Smad3, whereas Azacytidine had no significant effect (data 
not shown). When we preformed ChIP assay using Sp1, a known transcription repressor 
shown to be involved in Smad3 transcription (Lee, Elmer et al. 2004), we observed an 
increase in occupancy of Sp1 on the Smad3 promoter in the 300-days CSC treated cells 
and it vanishes due to Sodium Butyrate treatment (Fig. 18D). These results suggest that 
long-term CSC treatment decreases Smad3 mRNA and Smad3 promoter activity and 
histone deacetylation may play a role in reducing the Smad3 expression.   
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Figure 18.  Long-term CSC treatment decreases expression of Smad3 at both 
protein and mRNA level and the decrease is correlated to histone deacetylation 
A. Quantitative RT-PCR: Quantitative RT-PCR was used to determine the fold decrease 
of Smad3 mRNA, normalized to internal control GAPDH. The fold decrease was 
calculated by normalizing to the level of Smad3 mRNA in the corresponding DMSO 
treated samples. Long term CSC treatment significantly reduced the Smad3 mRNA 
compared to controls (* p< 0.001).  
B. Reporter assay: 4, 100 and 300-day CSC treated cells were transiently transfected 
Smad3 promoter reporter in both HPL1A and A549 cells. Luciferase activity was 
normalized to β-gal activity, and the relative luciferase activity was expressed.  Long 
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term CSC treatment significantly decreased the Smad3 promoter activity (* p< 0.001) in 
both cell lines 
C. 300-day treated A549 and HPL1A cell lines were treated with either HDAC inhibitor 
or Sodium Butyrate (1, 2, 3mM) and the protein levels were checked by immunoblot 
analysis using anti-Smad3 antibody. An equal amount of protein loading was verified by 
immunoblot analysis with anti-β-actin monoclonal antibody. 
D.  ChIP assay: ChIP assay was performed on 300-day CSC and DMSO treated samples 
to determine the occupancy of transcriptional repressor Sp1 on the Smad3 promoter.  The 
sixth lane from the left shows the occupancy of Sp1 on the Smad3 promoter due to 300-
day CSC treatment. The occupancy of Sp1 on Smad3 promoter vanishes due to HDAC 
treatment.  
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CSC treatment inhibits TGF‐β‐induced growth suppression and attenuates 
apoptosis by up-regulation of Bcl-2 
To determine if long-term CSC treatment has any effect on cell viability, we 
checked for cell viability by MTT assay in both A549 and HPL1A cells. We also tested 
whether the decrease in the Smad-dependent TGF-β signaling has any effect on TGF-β-
induced growth suppression. We found that the long-term CSC treated cells grew faster 
than the corresponding DMSO treated cells. We also observed that the TGF-β-induced 
growth suppression was diminished in the long term CSC treated cells (Fig. 19A). These 
data suggest that long-term CSC treatment increases cell growth and decreases TGF-β-
induced growth suppression. The increase in cell viability could be due to an increase in 
cell proliferation or decrease in apoptosis. We tested the cell proliferation by Thymidine 
incorporation assay. We did not see a significant change in cell proliferation by long-term 
CSC treatment (data not shown). To determine whether CSC treatment has any effect on 
apoptosis, we performed quantitative ELISA assay, which detects the cytoplasmic histone 
associated DNA fragments (mono and oligonucleosomes) after cell death. We found that 
long-term CSC treatment (300-days) of both A549 and HPL1A cells led to less apoptosis 
in CSC treated cells compared to their corresponding DMSO controls (Fig. 19B), 
suggesting a role of long‐term smoking in inhibiting apoptosis. This was confirmed by a 
qualitative DNA laddering assay in which the 300-day DMSO treated cells showed much 
more DNA laddering than the corresponding CSC treated cells (Fig. 19C). To understand 
the mechanism of decreased apoptosis, we assayed a number of important apoptotic 
regulators including Bcl-2, Bcl-xl, Bcl-w, and Bax in CSC treated A549 and HPL1A 
cells. Immunoblot analyses indicated that the level of anti-apoptotic Bcl-2 was up- 
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Figure 19. Long-term CSC treatment inhibits TGF-β-induced growth suppression 
and apoptosis. 
A. Cell viability of CSC treated cells in presence and absence of TGF-β determined by 
MTT assay. Long term CSC treatment significantly increased the growth in absence of 
TGF-β(* p< 0.001), and in presence of TGF-β(# p <0.001) in both cell lines. 
B. Quantitative cell death by ELISA in the various time points of CSC treated cells. Long 
term CSC treatment decreases the apoptosis significantly (* p< 0.001) in both cell lines.  
C. DNA laddering of A549, HPL1A 300-day CSC and DMSO treated cells cultured in 
serum-free medium for 72 hours.  
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regulated in cell extracts prepared from the 300-day CSC treated cells. No detectable 
change of other members of the Bcl-2 family was observed (Fig. 20A), and the pro-
apoptotic members namely Bax remains unchanged. To validate whether Bcl-2 is the 
cause of increase in apoptosis, we performed Bcl-2-siRNA knockdown in the 300-day 
CSC treated A549 and HPL1A cells. We assayed for apoptosis 72 hours after transfection 
of 20 nM of each Bcl-2 siRNA and scrambled control. We observed that apoptosis goes 
up (Fig. 20C) upon Bcl-2 knockdown. Simultaneously, we also checked the protein 
expression of Bcl-2 to confirm whether Bcl-2 levels are decreasing (Fig. 20B). Since NF-
kB is known to up-regulate Bcl-2 and to rule out the possibility that NF-kB is responsible 
for up-regulating Bcl-2, we checked the expression of NF-kB in the long-term CSC 
treated cells. We do not see an increase of NF-kB (p65) levels (Fig. 20D) due to long-
term CSC treatment, suggesting the up-regulation of Bcl-2 is not dependent on NF-kB in 
our model system. These results suggest that CSC treatment increases cell viability by 
decreasing apoptosis through up-regulation of anti-apoptotic Bcl-2.   
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Figure 20. Long term CSC treatment decreases apoptosis by increasing Bcl2 
independent of NF-kB. 
A. Cell lysates from various time points of CSC treatment were analyzed by immunoblot 
analysis with pro-apoptotic anti-Bcl-2, anti-Bcl-xl, anti-Bcl-w, and anti-apoptotic Bax 
antibody. An equal amount of protein loading was verified by immunoblot analysis with 
anti-β-actin antibody. 
B and C. 300-day CSC treated cells were transiently transfected with (20nM) of each 
Bcl-2 siRNA and assayed for apoptosis by FACS analysis. (B) Western blot showing the 
knockdown of Bcl2 in the 300-day CSC treated cells. (C) The percentages of cells 
59 
 
undergoing apoptosis are represented in the graph. Knocking down Bcl-2 increases the 
apoptosis in long term CSC treated cells significantly (* p<0.001) in both cell lines.   
D. Cell lysates from various time points of CSC treatment in both A549 and HPL1A cells 
were analyzed by immunoblot analysis with NF-κB. An equal amount of protein loading 
was verified by immunoblot analysis with anti-β-actin antibody. 
 
Withdrawal of CSC treatment restores TGF-β signaling and apoptosis 
After smoking cessation, the cumulative death risk from lung cancer decreases. 
Peto et al. showed that, the earlier cigarette smoking is stopped the greater the decline in 
lung cancer mortality (Peto, Darby et al. 2000). There is a pressing need to clarify the 
role of smoking cessation in the care of lung cancer patients. To mimic the conditions of 
smoking cessation, we withdrew cells from the long-term (300-day) CSC treatment and 
tested the effects on TGF-β signaling. We observed that Smad3-Smad4 complex 
formation goes up with the withdrawal of CSC treatment in the 300-day CSC treated 
samples. Thus, the Smad-dependent TGF-β signaling is restored together with Smad3 
expression (Fig. 21A). To test whether this restoration in TGF-β signaling translates to 
biological outcomes namely a decrease in cell viability, MTT assay was performed using 
both A549 and HPL1A cells after withdrawing CSC treatment. We saw that cell viability 
decreases and TGF-β mediated growth inhibition increases with withdrawal of CSC 
treatment (Fig. 21B). To test whether withdrawal of CSC treatment has any effect on 
apoptosis of cells, we performed cell death with the ELISA assay. Withdrawal of CSC 
treatment brings back apoptosis (Fig. 21C). These results suggest that the effect of CSC 
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treatment is reversible and that the withdrawal of CSC treatment restores TGF-β 
signaling, apoptosis and reduce cell viability. 
 
 
 
Figure21. Withdrawal of CSC treatment restores Smad-dependent TGF-β Signaling 
and apoptosis. 
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A. Cell lysates from 7 and 14 day CSC withdrawal cells after treatment with CSC for 300 
days were treated with TGF-β for 1 hour were  immunoprecipitated with anti-Smad3 and 
immunoblotted for anti-Smad4. 
B.  Cell viability of 300-day CSC and 7-, 14- day CSC withdrawal cells in presence and 
absence of TGF-β determined by MTT assay. Withdrawal of CSC treatment significantly 
decreased the growth in absence of TGF-β(* p< 0.001), and in presence of TGF-β(# p 
<0.001) in both cell lines. 
C.  Quantitative cell death by ELISA in the 300-day CSC treated and 7, 14 days CSC 
withdrawal cells. Withdrawal of CSC treatment significantly increases the apoptosis (* 
p< 0.001) in both cell lines.   
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Stable expression of Smad3 restores TGF-β signaling, apoptosis and reduces cell 
viability in long-term CSC treated cells 
CSC contains thousands of compounds comprising five known human 
carcinogens and many toxic agents. These may affect many different pathways ultimately 
leading to increased cell viability and altered apoptosis. To verify that the increase in cell 
viability is due to the decrease in Smad3 expression we performed rescue experiments, 
where we overexpressed Smad3 in 300-day CSC treated cells (Fig. 22A). Stable 
overexpression of Smad3 in both the 300-day CSC treated cell lines, HPL1A and A549, 
brought TGF-β signaling back as demonstrated by the luciferase assays with TGF-β 
responsive reporter elements both p-3TP-Lux and (CAGA)9-MLP ( Fig. 22 B and 22C). 
Similarly, the biological outcomes of the long-term CSC treatment increased cell viability 
and decreased apoptosis were also rescued by overexpression of Smad3. We observed 
that clones of Smad3 overexpressing in both 300-day CSC treated HPL1A and A549 cell 
lines underwent more apoptosis compared to the 300-day CSC treated HPL1A and A549 
cell lines and vector controls when we performed cell death by ELISA (Fig. 23 A and B, 
left panels). We observed that the same clones were less viable compared to the 300-day 
CSC treated HPL1A and A549 cell lines and the vector controls (Fig. 23A and B, right 
panels). These combined results suggest that the increase in cell viability by decreasing 
apoptosis is imparted via long-term CSC treatment, partly through down-regulation of 
Smad3.  
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Figure 22.  Stable expression of Smad3 restores TGF-β signaling. 
A. Cell lysates from parental, vector control, and three stable Smad3 overexpression 
clones were analyzed for overexpression of exogenous Smad3 by immunoblotting with 
anti-Smad3 antibody (left). β-Actin was used as a loading control for an equal amount of 
proteins. 
B,C.  Luciferase assays were performed 300-day CSC treated A549 (B) and HPL1A (C) 
cells stably transfected with Smad3 expression plasmid. Cells along with vector controls 
were transiently transfected with CMV-β gal, and p3TP-Lux-Luc or (CAGA)9-MLP-Luc 
reporter plasmids. Transfected cells were incubated in 0.2% FBS containing medium 
with 5 ng/ml TGF-β1 for 22 hours. Cell lysates were used to measure both luciferase and 
β-gal activities and the normalized luciferase activity was presented. 
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Figure 23. Stable expression of Smad3 reduces cell viability and induces apoptosis in 
300-day CSC treated cells. 
Cell viability by MTT assay and quantitative cell death by ELISA. Cells from parental, 
vector control and three stable Smad3 clones were tested for cell viability both in 
presence and absence of TGF-β (5ng/ml)(right panels) and apoptosis by ELISA (left 
panels) in 300-day A549 (A) and in HPL1A (B). Overexpression of Smad3 significantly 
increased apoptosis (++ p<0.001),   decreased growth in absence of TGF-β (* p< 0.001), 
decrease in growth in presence of TGF-β ( # p <0.001) in both cell lines. 
A 
B 
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Long-term CSC treatment enhances tumorigenicity of the cell both in vitro and in 
vivo partly by down-regulating Smad3 
Since the increase in cell viability and decrease in apoptosis by chronic exposure 
of cells to CSC are reminiscent of the phenotypes characteristic of oncogenically 
transformed cells, we next examined whether CSC treated cells were capable of 
anchorage independent growth by culturing them in soft agar. We performed soft agar 
assay using CSC treated A549 cells along with corresponding DMSO controls. The size 
and the number of colonies in the 300-day CSC-exposed cells were increased 
significantly when compared to the corresponding DMSO treated cells (Fig. 24A). We 
also observed that 300-day CSC treated A549 cells formed tumors bigger and faster than 
the 300-day DMSO and parental A549 cells (Fig. 24B). Taken together, these data 
suggest chronic CSC treatment not only enhances oncogenic transformation as elucidated 
by the soft agar assay but also enhances the tumorigenicity in the A549 cells. 
To verify that the increase in anchorage independent growth and tumorigenicity is 
due to the decrease in Smad3 expression we performed rescue experiments, where we 
overexpressed Smad3 in 300-day CSC treated cells. We performed soft agar assay using 
Smad3 overexpression clones and the corresponding vector controls. The number and the 
size of colonies were fewer in the Smad3 overexpression clones when compared to the 
vector controls and 300-day CSC treated cells (Fig. 25A). We also observed that the 
tumors formed in nude mice by Smad3 overexpression clones were smaller and slower 
than the vector controls and 300-day CSC treated cells (Fig. 25B). Taken together, these 
data suggest that long-term CSC treatment partly enhances the tumorigenicity of the 
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cells, and thus, partly contributes to smoking-induced lung cancer development by 
reducing the levels of Smad3.  
 
 
 
 
 
 
Figure 24. Long-term CSC treatment increases anchorage-independent growth and 
increases tumorigenicity. 
A. Growth in soft agar of A549 and various time points of CSC exposed cells. Pictures of 
colonies grown in soft agarose (bottom). Quantification of the colonies is shown on the 
top. Columns, average of three independent values determined from three plates (top); 
bars, SD. Long term CSC treatment significantly increased the number of colonies (* p< 
0.001).   
B. Cells from parental, 300-day CSC and 300-day DMSO were injected s.c. in athymic 
nude mice. The animals were monitored for tumor formation for a total of 12 weeks. 
Tumors were measured externally and volume was determined. Points, mean volume of 
tumors from four mice in each group; bars, SD.  Long term CSC treatment significantly 
increased the tumor volume (* p< 0.001) and produced tumors faster (# p<0.01). 
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Figure 25. Long-term CSC treatment increases anchorage-independent growth and 
increases tumorigenicity partly by down regulation of Smad3. 
A. Growth in soft agar assay of Smad3 overexpressing 300-day CSC treated A549 and 
vector control cells. Pictures of colonies grown in soft agarose (bottom). Quantification 
of colonies is shown on the top. Columns, average of three independent values 
determined from three plates (top); bars, SD.  Overexpression of Smad3 decreased the 
number of colonies significantly (* p< 0.001). 
B. Cells from A549 300-day CSC and Smad3 overexpressed A549 300-day CSC treated, 
along with vector control were injected s.c. in athymic nude mice and monitored for 
tumor formation for a total of 12 weeks. Tumors were measured externally and volume 
was determined. Points, mean volume of tumors from four mice in each group; bars, SE. 
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Overexpression of Smad3 in long term CSC treated cells decreased the tumor volume 
significantly (* p< 0.001). 
Smad3 status and its correlation with patient survival and smoking 
To elucidate the clinical relevance of our in vitro results that Smad3 expression 
goes down due to long-term CSC treatment, we performed immunohistochemical 
staining of tissue micro array (TMA) using the anti-Smad3 antibody. We observed that 
the staining of Smad3 in cancer cells was mostly nuclear (Fig 26). We also observed 
strong staining of Smad3 in the stroma and macrophages. The frequency of positive 
staining (>0) was more in the case of adenocarcinoma compared to the other 
subcategories of lung cancer namely small cell lung cancer, squamous cell lung cancer 
and carcinoma. We plotted the intensity scores of smokers and non-smokers and we 
observed that the Smad3 intensity scores was less in smokers than nonsmokers (Fig. 
27A).  When the staining intensities were correlated with survival status of the 
corresponding patients, the tumor-related survival was much better for the tumors with a 
high intensity (>2) of Smad3 staining compared to those tumors with a low intensity (<2) 
(Fig. 27B).  To further strengthen our observations, we looked into a public database 
(Shedden, Taylor et al. 2008) to check the Smad3 mRNA expression in smokers, never-
smokers and former-smokers in lung cancer patients. We found that Smad3 is expressed 
in lower levels in smokers compared to never-smokers (p=0.0396); Smad3 expression is 
lower in former-smokers compared to never-smokers (p=0.0254) (Fig. 28). Taken 
together these data suggests that Smad3 expression is lower in lung cancer patients who 
are current smokers and former-smokers compared to never-smokers. 
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Figure 26. Smad3 immunohistochemistry and tumor-related survival in lung cancer 
patients. 
A. Representative images of immunohistochemistry staining for Smad3 in lung cancer 
patients (200X Magnification). 
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Figure 27.  Quantitation of Smad3 immunohistochemistry and tumor-related 
survival in lung cancer patients. 
A. Box plot for Correlating Smad3 and smoking: Smokers (including current smokers 
and former-smokers) and never-smokers were categorized and Smad3 intensity scores 
(Intensity X Percentage of Cells) were plotted and the box plot was generated. * p= 0.15 
for intensity scores of Smad3 by t-test.  
B.  Kaplan-Meier Curve for tumor related survival status based on Smad3 status. Patients 
with high Smad3 tumors (Intensity >=2) were compared to patients with moderate or low 
expressions of Smad3 (Intensity 0, 1 and 2). * p= 0.75 by log rank test.  
A B 
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Figure 27.  Smad3 expression according to the smoking status. 
Scatter plot for Smad3 from Shedden et al. 2008: Gene expression normalized z scores of 
Smad3 from lung cancer patients are plotted categorized by smoking status into Current 
smokers, Never-Smokers and Former-smokers. p values were calculated for the pairs 
shown by t-test. 
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Discussion 
 
Lung carcinogenesis involves the accumulation of genetic and epigenetic changes 
that accumulate over a long course due to chronic smoking or other genetic susceptibility 
factors (Herbst, Heymach et al. 2008).One of the putative problems in all previous studies 
is that the cells were treated with tobacco constituents for a maximum of 10 days. As a 
result, short-term exposure to cigarette smoke cannot be a true representation of lung 
cancer, which mainly occurs in long-term smokers.  
In this study, we have shown that long-term exposure to CSC can damage lung 
epithelial cells, inducing hyperplasic growth and carcinogenesis. Our results reveal that 
SV40-immortalized bronchial epithelial HPL1A cells and lung adenocarcinoma cell line 
A549 surviving 300 days of repeated CSC exposure are endowed with some phenotypic 
changes that are characteristic of oncogenic transformation: alteration in growth kinetics, 
decrease in the tumor suppressing effects of TGF-β, decrease in apoptosis due to an 
increase in oncogenic anti-apoptotic Bcl-2. In addition, the A549 cell line with 300 days 
of CSC treatment has increased anchorage independent growth, and more importantly, 
the ability to produce tumors in nude mice (Fig.24). Therefore, this approach of treating 
cells long-term with CSC at low concentration, offers a new tool to study the biology of 
lung cancer in long-term smokers. One putative issue in culturing the HPL1A cells could 
be culturing these cells in media supplemented with 10% FBS instead of 1% FBS that 
was used for establishing the cell line (Masuda, Kondo et al. 1997)). We have used 10% 
FBS containing medium to culture these cells for several reasons, 1) there are no changes 
in TGF-ß signaling when these cells are grown in 10% serum (Yanagisawa, Osada et al. 
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1998)  , 2) 10% FBS containing medium was used to grow HPL1A cells before (Sato, 
Yazawa et al. 2006), 3) HPL1A cells cannot survive long-term (300 days) in culture 
without serum  and  4) TGF-ß-induced transcriptional regulation and growth inhibition 
(Fig. 17, A, B right panels and  Fig. 19A) were not affected and these cells did not 
become tumorigenic when grown in 10% serum containing medium (data not shown). 
In the present study, an in vitro model system was used to gain insight regarding 
how Smad dependent TGF-β signaling alterations potentially contribute to the initiation 
and early progression of smoking-induced lung cancers. We show that long-term CSC 
treatment results in the reduced expression of Smad3 (Fig. 16). We have observed 
decreased Smad3-Smad4 complex formation and reduced TGF-β-induced transcription 
from p3TP-Lux and (CAGA)9-MLP-Luc reporters (Fig. 17 A and B). This suggests that 
reduced expression of Smad3 inhibited TGF-β signaling. Functionally, Smad3 reductions 
lead to an increase in cell viability. The increase in cell viability was due to decreased 
apoptosis. This decrease in apoptosis was due to up-regulation in anti-apoptotic Bcl-2, as 
seen in the chemically induced model of HCC (Yang, Zhang et al. 2006) (Fig. 20A).  
We also observed that the long-term CSC treatment increases the tumorigenicity 
of the cells (Fig. 24 A and B). Cigarette smoke contains about 4800 chemical agents 
including more than 60 known human carcinogens (Hoffmann, Hoffmann et al. 2001). 
The increase in tumorigenicity could be due to the activation of oncogenic pathways 
and/or inactivation of the tumor suppressive signaling cascade. In an attempt to elucidate 
the role of reduced expression of Smad3 in response to CSC treatment, we have observed 
that restoration of Smad3 expression in long-term CSC treated cells reduces 
tumorigenicity (Fig. 25 A and B). These results suggest that smoking-induced lung 
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cancer progression is partly due to the reduction in Smad3 expression and attenuated 
TGF-β tumor suppressor function. This is in agreement with the previous data that 
ectopic expression of Smad3 reduces the susceptibility to hepatocellular carcinoma 
(HCC) in a chemically induced murine model, consolidating the evidence for the tumor 
suppressor function of Smad3 (Yang, Zhang et al. 2006).  
The failure of the long-term CSC treated HPL1A cells to grow in soft agar or 
orthotopically in nude mice (data not shown) indicates that additional alterations are 
required to facilitate tumor formation. The ability to confer a complete malignant 
phenotype would likely require additional epigenetic or genetic changes. Only A549 cells 
bear a K-ras codon 12 mutation (Takezawa, Okamoto et al. 2009). We observed 
enhanced tumorigenicity in long-term CSC treated A549 cells both in vitro and in vivo 
(Fig. 24 A and B). Therefore, one plausible explanation is that the K-ras mutation, which 
is present only in A549 cells, is contributing to the tumorigenicity in vitro and in vivo.  
We next validated the conclusions drawn from the in vitro model in real life 
smokers using lung tumors of patients and public database, which provides the largest 
available set of microarray data with extensive pathologic and clinical annotation for lung 
adenocarcinomas (supporting material).  In our TMA staining we saw a trend that the 
expression of Smad3 is less in smokers compared to non-smokers. Similarly, in public 
database we found that Smad3 expression is less in current smokers compared to the 
never-smokers and former-smokers. Thus, we showed the relevance of Smad3 
expression, which is down-regulated in our in vitro model, to lung adenocarcinoma gene 
expression pattern found in smokers. To our knowledge, this is first time; Smad3 is 
correlated with the smoking status of lung cancer patients.  
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Our results reveal, for the first time, that a smoking-mediated decrease in Smad3 
expression plays a key role in the induction of lung cancer by increasing cell viability and 
decreasing apoptosis. This is in accordance with the expression of Smad3 from clinical 
patient samples which correlates with the results obtained from our in vitro system. Since 
the decrease in Smad3 expression is reversible, it would suggest that it happens in the 
early phases of smoking-induced lung cancer. Hence, it can be potentially used as a 
biomarker for smoking-induced lung cancer. 
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CHAPTER IV 
Introduction 
Lung cancer is the leading cause of cancer-related deaths worldwide (Siegel, 
Naishadham et al. 2012). Cigarette smoking is a major risk factor in the development of 
non-small cell lung cancer (NSCLC), which accounts for 80% of all lung cancers (Minna, 
Fong et al. 2002; Sekido, Fong et al. 2003). Current standard therapies include surgical 
resection, platinum-based doublet chemotherapy, and radiation therapy alone or in 
combination. Unfortunately, these therapies rarely cure the disease, and the overall 5-year 
survival rate is still only 15% (Siegel, Naishadham et al. 2012). NSCLC is characterized 
by its poor prognosis and resistance to the apoptotic activity of anti-neoplastic drugs both 
in vivo and in vitro (Bepler 2003; Katakami, Sugiura et al. 2004).  
cis-Diamminedichloroplatinum (II) Cisplatin, carboplatin and oxaliplatin are 
platinum-based drugs that are widely used in cancer chemotherapy. These agents are 
commonly administered in various tumor types including ovarian, cervical, head and 
neck, and non-small-cell lung cancer (Kelland 2007). Due to the low chloride ion 
concentration in the cell, cisplatin undergoes aquation to form (Pt (NH3)2Cl (OH2)) + 
and (Pt (NH3)2(OH2)2)2+ once inside the cell. Although many cellular components 
interact with cisplatin, DNA is the primary biological target of the drug (Jamieson and 
Lippard 1999). The platinum atom of cisplatin forms covalent bonds to the N7 positions 
of purine bases to afford primarily 1, 2- or 1, 3-intrastrand crosslinks and a lower number 
of interstrand crosslinks. The final cellular outcome of DNA adduct formation is 
generally apoptotic cell death. Apoptosis is thought to occur through halting of cellular 
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processes such as replication and transcription, leading to prolonged G2 phase cell cycle 
arrest and deregulation of signal transduction pathways involved in normal homeostasis 
of the cell, response to stress (Siddik 2003; Stewart 2007). Many factors contribute to the 
cellular mechanisms of resistance to platinum-based chemotherapeutics and contribute to 
a severe limitation in their use in clinical practice. One important mechanism acting 
downstream of the initial reaction of cisplatin with DNA is an increase in adduct repair 
and a decrease in the induction of apoptosis (Siddik 2003). Among the significant cellular 
pathways that have been demonstrated to play key roles in platin-induced 
apoptosis/cytotoxicity, the mitogen-activated protein kinase (MAPK) cascades, and the 
tumor suppressor p53 (Manic, Gatti et al. 2003; Sedletska, Giraud-Panis et al. 2005). 
Deciphering the mechanisms involved in chemoresistance is critical to improve our 
understanding of these complex pathways and to develop more effective targeted 
treatments.  
Tumor cells often respond to chemotherapy by engaging protective mechanisms 
and survival signaling, which can antagonize the chemotherapy (Mayo and Baldwin 
2000). Furthermore, apoptosis inhibition is necessary to provide cancer cells with the 
ability to survive in a stressful environment; it has been proposed that oncogenes provide 
cancer cells with intrinsic resistance. Chemoresistance in several types of cancer has been 
linked to the up-regulation of Bcl2 (Fesik 2005). Overexpression of Bcl2 is associated 
with cisplatin resistance, and this is likely facilitated by an increase in GSH levels 
(Hockenbery, Oltvai et al. 1993; Chiao, Carothers et al. 1995). However there are 
paradoxical findings, which indicate that Bcl2 overexpression is associated with either 
improved survival of ovarian cancer patients receiving cisplatin (Herod, Eliopoulos et al. 
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1996) or increased sensitivity of tumor cells to cisplatin (Beale, Rogers et al. 2000). So 
far, however, it has not been investigated whether overexpression of Bcl2 that is observed 
in smokers with NSCLC, is only an epiphenomenon or whether it is mechanistically 
involved in the development of drug resistance.  
 Cigarette smoking has been found to induce a number of genetic and molecular 
changes in the respiratory tract, including cellular atypia, loss of heterozygosity (Powell, 
Klares et al. 1999), and promoter hyper methylation (Guo, Akiyama et al. 2004). 
Microarray studies of bronchial epithelial cells have indicated that cigarette smoke 
induces, primarily, the expression of xenobiotic‐metabolizing and redox‐regulating genes 
but also points to the effects on tumor suppressor genes, oncogenes, and genes involved 
in the regulation of inflammation (Spira, Beane et al. 2004). Systematic analysis of 
mRNA and protein expression levels among thousands of genes has also contributed to 
defining the molecular network of lung carcinogenesis. Despite the fact that enormous 
progress in understanding the molecular mechanisms leading to lung cancer has been 
made, very little attention has been paid to how these molecular changes affect 
chemotherapy in smokers.   
The transforming growth factor-beta (TGF-β) pathway has important roles in 
cellular proliferation, angiogenesis, differentiation, migration and apoptosis.  The TGF-β 
pathway signal either through the SMAD-dependent pathway or SMAD independent 
pathway such as extracellular signal-regulated kinase, c-jun N-terminal kinase, 
PI3K/AKT and Rho-like guanosine triphosphatases. Despite the prominent role TGF-β 
pathway appears to play in regulating multiple cellular processes, there have not been any 
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studies elucidating the effect of this pathway on the resistance to chemotherapy in lung 
cancer. 
Recent reports show that nicotine inhibits apoptosis in various cells lines, which 
may suggest that nicotine has the ability to reduce the efficacy of chemotherapeutic 
agents by stimulating survival pathways (Heeschen, Jang et al. 2001; Minna 2003; 
Dasgupta, Kinkade et al. 2006). In addition to nicotine, a burning cigarette generates as 
many as 6000 other compounds, amongst which 60 of them are known to be carcinogens.  
Although the toxicity of individual components can be assessed, it is likely that the 
biological response to complex mixtures such as cigarette smoke is not the sum of 
multiple independent toxicities. The best methodology to mimic effect of smoking in 
humans in vitro, would be to treat human lung cell lines with CSC and examine how that 
affects chemotherapy in lung cancer patients.  
In our previous publication, we found that the Smad3 pathway is down regulated 
in long-term CSC treated cells and it contributes to lung tumorigenesis. In that paper we 
found that reduced expression of Smad3 due to long-term CSC treatment made the cells 
resistant to apoptosis, we conjectured that the Smad-dependent TGF-β pathway might 
also contribute to the resistance to chemotherapy of lung cancer patients. To answer that 
question we determined the IC50 of Carboplatin in the long-term CSC treated cells and 
elucidated how this pathway contributes to the resistance to carboplatin. 
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Results 
Long-term CSC treatment imparts Carboplatin resistance 
In our previous study, we have shown that long-term CSC treatment increases cell 
viability by decreasing apoptosis through up-regulation of anti-apoptotic Bcl2. To test 
whether long-term cigarette smoking contributes to the resistance to Carboplatin-based 
chemotherapy in lung cancer, we analyzed the cytotoxic effects of carboplatin treatment 
on a various time points of CSC treated  A549 (lung adenocarcinoma) and HPL1A 
(immortalized bronchial epithelial) cell lines using the MTT cell viability assay. The 
long-term CSC treated cells (300-day CSC treated) were much more resistant to 
carboplatin treatment compared to the corresponding control (300-day DMSO treated) 
cells. In A549, the I.C.50 of Carboplatin for long-term (300-day) CSC treated cells was 
167.5 µM whereas the corresponding control (300-day DMSO) cells had an I.C.50 of 
72.3 µM (Fig. 1A). We saw the similar effect in HPL1A cells. The IC50 of 300-day CSC 
treated cells was 131.7 µM, whereas the IC50 of 300-day DMSO treated cells was 55.0 
µM (Fig. 1B). Additionally, we observed that the IC50 of the cell lines increased with the 
increasing time of treatment of CSC. Bim, a pro-apoptotic factor is a downstream target 
of Smad3. Since in our previous study we elucidated that Smad3 expression goes down in 
long-term CSC treatment, we wanted to examine whether the expression levels of Bim 
are affected. To answer the question, we performed immunoblot analyses with the cell 
lysates prepared from long-term CSC treated cells and control cells. There was no 
difference in the expression of Bim in the long-term CSC treated A549 and HPL1A cells 
(Fig. 1C). Resistance to the cytotoxic effects of carboplatin in the long-term CSC treated 
cells lines were evidenced by a plateau pattern at lower doses of treatment. Taken  
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Figure 29. Long-term CSC treatment makes the cells resistant to Carboplatin due to 
up-regulation of Bcl2  
A, B. 300-day CSC treated cells and 300-day DMSO treated (control) A549 (A) and 
HPL1A (B) cells were treated with Carboplatin for 72 hours, and cell viability was 
assessed as measured by MTT activity. Data are represented as a percentage of MTT 
activity where untreated cells were taken to be 100%. The I.C.50 and the corresponding 
S.D. were calculated from 6 individual experiments.  
C, D.  Bim expression 300-day CSC treated samples and controls in (C) A549 and (D) 
HPL1A cells by Western Blot analysis. β-Actin was used as a loading control. 
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together, these results may suggest that long-term CSC treatment makes the cells resistant 
to carboplatin-based chemotherapy. 
CSC treatment induces resistance to Carboplatin by abrogating apoptosis 
It is known that in many cases the cells become resistant to chemotherapeutic drugs due 
to less induction of apoptosis by drugs. To test whether apoptosis is playing a role in CSC 
induced resistance, we conducted apoptosis studies by FACS analyses. 300-day DMSO 
and CSC treated cells were treated with fixed concentration of Carboplatin for 48 hours 
and then analyzed for apoptosis induced by Annexin V-PI staining. We observed that in 
the control cells Carboplatin induced a higher percentage of cell death (28 for HPL1A 
and 20 for A549) compared to the corresponding CSC treated cells (4 for HPL1A and 3 
for A549) (Fig. 30 B and D). Thus, the long-term CSC treatment abrogated carboplatin-
mediated apoptosis in both cell lines. To confirm the induction of apoptosis by another 
method, we performed immunoblot analysis of cleaved PARP, another hallmark of 
apoptosis, on the samples with increasing concentration of Carboplatin for 48 hours. We 
observed a dose dependent increase in PAPR cleavage in the DMSO treated A549 and 
HPL1A cells. CSC treated cells did not show any PARP cleavage (Fig. 30 C and E). 
Carboplatin often cause cell cycle arrest in the G2/M phase. An arrest of the cells in the 
G2/M phase is seen as inhibitory to the cytotoxic processes of the drug. To test whether 
long-term CSC treatment causes the cells to be arrested more in the G2/M phase, in 
response to Carboplatin, we performed cell cycle analysis using FACS. Cells were treated 
with Carboplatin for 48 hours and the percentages of cells having 2N DNA content were 
quantitated (as a measure of G2/M phase). We observed that in the long-term CSC 
treated cells the carboplatin-induced arrest in the G2/M phase was higher than in the 
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corresponding control cells (Fig. 31). Taken together, these results suggest that long-term 
CSC treatment abrogates carboplatin-induced apoptosis by arresting the cells in the G2/M 
phase of the cell cycle. 
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Figure 30. Long-term CSC treatment makes cells resistant to Carboplatin through 
the abrogation of apoptosis. 
A. Representative of figures of Apoptosis detected by Annexin-V-PI staining on 300 day 
CSC treated and control for both A549 and HPL1A cells treated with carboplatin for 48 
hours.  
E A 
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B, D.  Quantitation of apoptosis detected by Annexin V-PI staining on the 300-day CSC 
treated and control for both A549 and HPL1A cells treated with Carboplatin 70 µM for 
72 hours analyzed by FACS analysis. Quantitation and statistical analysis were calculated 
from 4 individual experiments. 
C,E. Cleaved-PARP and Cleaved Caspase-3 expression in 300-day CSC treated and 
control A549; HPL1A cells after treated with increasing concentration of Carboplatin at 
35 µM and 70 µM for 48 hours. β-Actin was used as loading control. 
 
 
 
Figure 31. Long-term CSC treatment abrogates Carboplatin mediated apoptosis by 
arresting the cells in G2 phase of cell cycle. 
 Cell cycle analysis of 300-day CSC treated cells and control cells (300-day DMSO) after 
treatment with Carboplatin for 48 hours. Figure is a representative of four different 
experiments. 
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Bcl2 is important for the inhibition of Carboplatin-induced apoptosis 
CSC contains thousands of compounds, comprised of five known human carcinogens and 
many toxic agents. These may affect different pathways ultimately leading to increased 
carboplatin resistance. To test whether Bcl2 is involved in CSC induced chemoresistance, 
we performed rescue experiments by knocking down Bcl2 in long-term CSC treated cells 
by siRNA. We transfected Bcl2 siRNA and a control scrambled siRNA in the long-term 
CSC treated cells (both A549 and HPL1A). The next day, cells were treated with 
Carboplatin for 48 hours and checked for apoptosis by FACS analysis. Immunoblot 
analyses were performed at the same points to verify the knockdown of Bcl2 in the long-
term CSC treated cells (Fig. 32A and B, upper panels). In support of our hypothesis, we 
observed that on knocking down Bcl2 in the long-term CSC treated cells there is a 
significant increase in the induction of apoptosis in both the cell lines. These results 
suggest that Bcl2 is important for the long-term CSC treated cells to become resistant to 
carboplatin-mediated apoptosis. To confirm that Bcl2 is sufficient to make the cells 
resistant to carboplatin, we overexpressed exogenous Bcl2 in the parental A549 and 
HPL1A cells where the expression of Bcl2 is low (Fig. 33 A and B, upper panels). To test 
whether overexpression of Bcl2 decreases the sensitivity to Carboplatin mediated 
apoptosis, we treated the Bcl2 overexpressing clones along with parental and vector 
controls with Carboplatin for 48 hours. We observed that the Bcl2 overexpressing clones 
were resistant to Carboplatin mediated apoptosis compared to the parental and vector 
controls (Fig. 33 A and B, lower panels). We then determined the I.C.50 of Carboplatin 
in both the clones stably overexpressing Bcl2 along with the vector controls. Stable 
overexpression of Bcl2 in the parental A549 and HPL1A cells increased the I.C.50 of   
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Figure 32. Bcl2 is involved in making cells resistant to Carboplatin. 
A. Bcl2 expression in the 300-day CSC treated A549 and HPL1A cells transfected 
with siRNA directed against Bcl2 and scrambled control. β-Actin was used as a loading 
control. 
B. Percentage of apoptotic cells detected by Annexin V-PI staining in the 300-day 
CSC treated cells after no treatment (white) or after treatment with 70 µM Carboplatin 
(black) for 48 hours after transfection with siRNA against Bcl2 and scrambled control. 
Statistical analyses were calculated based on 4 individual experiments. 
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Figure 33. Overexpression of Bcl2 makes the cells resistant to Carboplatin induced 
apoptosis. 
 A, B. Bcl2 expression in the Bcl2 overexpressing clones in the (A)A549 and (B) 
HPL1A cells. β-Actin was used as a loading control.Fold induction of apoptosis by 
Annexin V-PI staining in parental, Bcl2 overexpressing clones, and vector control after 
treatment of 70 µM Carboplatin compared to no treatment of Carboplatin in the 
corresponding clones for 48 hours. Statistical analyses were calculated based on 4 
individual experiments. 
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C.  
 Figure 34. Over-expression of Bcl2 increases the I.C.50 of Carboplatin  
Parental A549 (left panel), HPL1A (right panel), Bcl2 overexpressing clones and vector 
controls were treated with varying concentration of Carboplatin for 72 hours and assayed 
for cell viability as measured by MTT activity. The I.C.50 was calculated as described in 
Materials and Methods. Standard deviations were calculated based on triplicate data 
points for each concentration. Statistical analyses were calculated based on 3 individual 
experiments. 
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Carboplatin in both cell lines (Fig. 34). The average I.C.50 of Carboplatin for Bcl2 
overexpression clones were 100 µM for A549 and 125 µM for HPL1A; whereas the 
average for the parental and vectors were 25 µM for A549 and 50 µM for HPL1A. Taken 
together, these experiments suggest that Bcl2 is necessary and sufficient for long-term 
CSC treated cells to make them resistant to Carboplatin induced apoptosis. 
ABT-737 sensitizes the long-term CSC treated cells to Carboplatin 
Numerous examples exist in the literature of an enhanced apoptotic response when the 
BH3 mimetics are combined with traditional therapies to treat various cancers such as 
melanoma, pancreatic, glioma, breast, multiple myeloma, and B‐cell malignant models 
(Witham, Valenti et al. 2007; Shoemaker, Mitten et al. 2008; Tse, Shoemaker et al. 
2008). We wanted to test whether BH3 mimetic ABT-737 would sensitize the cells to 
Carboplatin in our in vitro model system. First, we tested the effect of the ABT-737 on 
apoptosis in our model system. We treated the 300-day CSC treated cells and the control 
cells with increasing concentration of ABT-737 for 48 hours and assayed for apoptosis. 
We observed that ABT-737 induced more apoptosis in the 300-day CSC treated cells 
compared to the control cells in both A549 and HPL1A cells (Fig. 35 A and B, upper 
panels). The sensitivity of ABT-737 depends on the expression of another anti-apoptotic 
Bcl2 family protein, Mcl1 (van Delft, Wei et al. 2006). To test whether increased levels 
of Mcl1 is contributing to the increased resistance to ABT-737, we performed 
immunoblot analysis on the samples. We observed that the expression of Mcl1 does not 
change due to CSC treatment (Fig. 35A and B, lower panels). We can conclude that the 
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Figure 35. Long-term CSC treated cells are more sensitive to ABT-737. 
A,B. 300-day CSC treated (300-day DMSO as a control) A549 (A) (upper panel) and 
HPL1A (B)  (upper panel)cells were treated with increasing concentration of ABT-737 
for 48 hours and percentage of cells undergoing apoptosis were detected by Annexin V-
PI staining. Statistical analyses were calculated based on 4 individual experiments. Cell 
lysates from 300-dat CSC treatment and controls were analyzed by immunoblot analysis 
with pro-apoptotic anti-Mcl1 antibody. An equal amount of protein loading was verified 
by immunoblot analysis with anti-β-actin antibody (lower panels). 
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Figure 36. ABT-737 resensitizes the long-term CSC treated cells to carboplatin.  
A. Fold induction of apoptosis in 300-day CSC treated A549 and HPL1A cells along 
with control cells were treated with or without 70 μM carboplatin and increasing 
concentration of ABT-737 (0-1.5 μM) assayed by Annexin V-PI staining. Fold induction 
was calculated from the ratio of percentage of cells undergoing apoptosis undergoing 
treatment with respect to the apoptosis in the untreated samples. Error bars are 
representative of four independent experiments. 
B. 300-day CSC treated cells treated with carboplatin (0-250 μM) in the presence of 
increasing concentration of ABT-737 0;0.5;1.0;1.5 μM for A549 and 0;2.5;5;7.5 μM for 
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HPL1A cells for 72 hours were assessed for cell cytotoxicity as measured by MTT 
activity. The data are presented as a percentage of MTT activity where untreated cells 
were taken to be 100%. Error bars are representative of four independently treated 
samples. 
 
 
 
increased sensitivity of ABT-737 is not due to increased expression of Mcl1. Next, we 
wanted to test whether ABT-737 can sensitize the 300-day CSC treated cells selectively 
to Carboplatin mediated apoptosis. To test this hypothesis, we treated 300-day CSC 
treated cells along with control cells with same concentration of Carboplatin, and 
increasing concentration of ABT-737 for 48 hours and assayed for apoptosis by FACS 
analyses. We observed that the fold induction of apoptosis on top of Carboplatin by 
ABT-737 was higher in the 300-day CSC treated cells compared to the control cells (Fig. 
36 A). Next, we wanted to test whether the ABT-737 could sensitize the 300-day CSC 
treated cells to carboplatin. We determined the I.C.50 of Carboplatin with increasing 
concentrations of ABT-737. We observed that ABT-737 decreased the I.C.50 of 
Carboplatin in both the cell lines in a dose-dependent manner (Fig. 36 B). Taken 
together, these results prove the niche of ABT-737 to be used in combination with 
Carboplatin to improve the therapeutic efficacy.  
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Smad3 induces sensitivity of Carboplatin in long-term CSC treated cells by down-
regulating Bcl2 
In our previous studies, we have shown that the expression of Smad3 decreases in the 
long-term CSC treated cells. We also showed that it is associated with the increased 
expression of Bcl2. To test whether Smad3 can alter the sensitivity of long-term CSC, we 
stably overexpressed Smad3 in the 300-day CSC treated A549 and HPL1A cells. We then 
verified the overexpression of Smad3 in the 300-day CSC treated cell by Western blot 
analyses (Fig 37A, upper panel). To test whether Bcl2 is regulated by Smad3, we 
performed Western blot on the Smad3 overexpression clones to check the expression of 
Bcl2. We observed that Bcl2 expression is reduced in the Smad3 overexpression clones 
(Fig 37A, middle panel). Next, we wanted to test whether re-expression of Smad3 can re-
sensitize the cells to carboplatin-mediated apoptosis. We treated the Smad3 
overexpressing clones, vector control and the 300-day CSC treated cells (both A549 and 
HPL1A) with Carboplatin for 48 hours and assayed for apoptosis. We observed that 
Smad3 overexpressing clones showed a much higher fold induction in apoptosis than the 
300-day CSC treated and the vector controls (Fig. 37B). We extended the results further 
and tested whether the Smad3 overexpression can actually sensitize (decrease the I.C.50)  
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Figure37. Smad3 expression mediates, in part, the cytotoxic effects of carboplatin. 
A. Protein expression of Smad3, Bcl2 in Smad3 overexpressing clones, vector 
control in the 300-day CSC treated A549 and HPL1A cells. An equal amount of protein 
loading was verified by immunoblot analysis with anti-β-actin antibody. 
A 
B 
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B. Fold induction of apoptosis in the 300-day CSC treated cells, vector controls and 
Smad3 overexpressing clones after treatment of 70 μM carboplatin for 48 hours. Fold 
induction was calculated from the ratio between percentage of cells undergoing apoptosis 
with treatment and without treatment of carboplatin in the corresponding cells. Error bars 
were calculated from four individual experiments. 
 
 
 Figure 38. Re-expression of stable Smad3 resensitizes the long-term CSC treated 
cells to Carboplatin 
300-day CSC treated A549 and HPL1A, Smad3 overexpressing clones and vector 
controls were treated with varying concentration of Carboplatin for 72 hours and assayed 
for cell viability as measured by MTT activity. The data are presented as a percentage of 
MTT activity where untreated cells were taken to be 100%. Error bars are representative 
of four independently treated samples. 
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the 300-day CSC treated cells to Carboplatin. We determined the I.C.50 of Carboplatin in 
the Smad3 overexpressing clones. We observed that the I.C.50 of Carboplatin was less in 
the Smad3 overexpressing clones compared to the parental (300-day CSC treated) and the 
vector controls in both A549 and HPL1A cell lines (Fig. 38). The average I.C.50 of 
Carboplatin for Smad3 overexpression clones were 85 µM for A549 and 100 µM for 
HPL1A; whereas the average for the parental and vector were 130 µM for A549 and 150 
µM for HPL1A cells. Taken together, these results suggest that Smad3 regulates the 
expression of Bcl2 and, in turn, controls the sensitivity of the 300-day CSC treated cells 
to Carboplatin. 
Loss of Smad3 expression in CSC treated cells induces resistance to Carboplatin by the 
up-regulation of Bcl2 
Smad3 has many downstream targets, and overexpression of Smad3 can regulate other 
pathways that may contribute to the increased sensitivity other than the down-regulation 
of Bcl2. We hypothesize that the sensitivity to Carboplatin mediated apoptosis in the 
Smad3 overexpressing clones is exclusively due to down-regulation of Bcl2 and not some 
off target effects. To test this hypothesis, we used Smad3 siRNA to suppress Smad3 
expression in the Bcl2 overexpressing clones in both A549 and HPL1A cells. 
Immunoblot analysis performed in parallel experiments demonstrated the successful 
knockdown of Smad3 in the Bcl2 overexpression clones (Fig. 39A and B, upper panels).  
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Figure 39. Smad3 makes the cells resistant to Carboplatin mediated apoptosis 
specifically through the Bcl2 pathway. 
A. Expression of Smad3, Bcl2 in the Bcl2 overexpressing clones of A549 and 
HPL1A cells after transfection of Smad3 siRNA and scrambled control by Western Blot. 
β-Actin was used as a loading control. 
B. Percentage of cells undergoing apoptosis in the Bcl2 overexpressing clones in 
A549 and HPL1A cells, after transfected with Smad3 siRNA and scrambled control and 
treated with carboplatin 50 µM for 48 hours. Error bars are calculated from four 
individual experiments. 
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The loss of Smad3 in the Bcl2 overexpressing clones did not induce apoptosis by 
Carboplatin treatment for 48 hours in both the cell lines (Fig 39A and B, below panels). 
Taken together, these results demonstrate that loss of Smad3 expression induces 
resistance to carboplatin in 300-day CSC treated cells specifically through Bcl2.  
Correlation between Smad3 and Bcl2 expression in lung tumors 
In our in vitro model system, we observed that Smad3 regulates the expression of Bcl2. 
Since it is an in vitro model system, it might be an artifact of long-term cells in culture. 
To verify whether the inverse correlation between the expression of Smad3 and Bcl2 is 
valid in lung tumors or not, we looked into the public database (Shedden, Taylor et al. 
2008) to investigate the correlation between Smad3 mRNA expression and Bcl2 mRNA 
expression. We found that lung cancer patients with higher levels of Smad3 have lower 
levels of Bcl2 and patients having lower levels of Smad3 have relatively higher levels of 
Bcl2 mRNA expression (Fig. 40). The results were statistically significant. This data 
suggest that an inverse correlation exists between the mRNA expressions of Smad3 and 
Bcl2 in lung tumors.  
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Figure 40. Smad3 and Bcl2 expressions are inversely correlated in non-small cell 
lung cancer. 
 Box plot of Bcl2 expression as a function of Smad3 expression status in patient tumor 
samples from public database. p values calculated by student t-test. 
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Discussion 
In this paper, we have used an in vitro system to mimic long-term smoking in 
human. We treated a tumor cell line (A549) and an immortalized bronchial epithelial cell 
line (HPL1A) with Cigarette smoke condensate (CSC) for various time points of 
treatment. Since the CSC is dissolved in DMSO, we also treated the cells with DMSO as 
a control, to take into account, if any, of the effects of long-term cell culture. We 
demonstrated that long-term CSC treatment makes the cells resistant to carboplatin, and 
Smad3 is partly responsible for making the cells resistant to chemotherapy. To our 
knowledge, this is the first time Smad3 has been shown to be responsible for creating 
resistance to chemotherapy in lung cancer. We also show, for the first time, that in 
NSCLC, there is an inverse correlation between the expression of Smad3 and Bcl2. 
Smad3 is a regulator of Bcl2 in lung cancer. 
Although progress has been made in the field of cancer treatment, no method is 
100% effective for success. One major obstacle in cancer treatment is the resistance of 
cancer cells to anticancer drug therapies. In fact, drug resistance is currently the most 
common factor in tumor recurrence. Resistance to therapy can be classified by two 
categories: intrinsic and acquired. Intrinsic resistance implies that prior to receiving the 
intended therapy; there already exists (de novo) factors that would make the intended 
therapy ineffective. During the course of treatment, tumors, that are not initially resistant 
to a particular drug, often quickly develop acquired resistance. This is because of the 
prevailing selection and overgrowth of drug-resistant variants in the tumor cells, resulting 
in the futility of that treatment (Blagosklonny 2004). Correctly selected targeted 
treatments are guaranteed to improve tumor response rates. The results from our current 
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study serve as examples of the utility of the in vitro model for defining the subset of 
patients with favorable outcomes in cell line systems. After appropriate preclinical 
validation, these suggestions are expected to lead to improved outcomes in clinics. 
According to our data, lung cancer patients who are/were long-term smokers are 
intrinsically resistant to carboplatin-based chemotherapy. 
Stabilization and activation of wild type p53 are critical for cisplatin-mediated 
apoptosis. Therefore, the tumor cells devoid of the wild type p53 function fail to activate 
the cell death program. Thus, the cells become tolerant to DNA damage, which is a 
feature characteristic of resistance caused by disruption in signal transduction pathways 
(Kastan, Onyekwere et al. 1991; Hartwell and Kastan 1994; Pietenpol, Tokino et al. 
1994; Siddik, Mims et al. 1998). However, the NCI panel of cell lines demonstrates a 
wide range of overlapping responses to cisplatin for the group of wild type and mutant 
p53 tumor models, with some mutant p53 models expressing exquisite cisplatin 
sensitivity (O'Connor, Jackman et al. 1997). These observations have also been 
documented in clinical cases, where tumors demonstrate either sensitivity or resistance to 
cisplatin irrespective of the p53 gene status (Righetti, Tosi et al. 1996). Similar to these 
observations, we also observed that the resistance to cisplatin is irrespective of the status 
of p53 (Fig. 29). In HPL1A cells, p53 is inactivated due to immortalization by SV-40 
large T-antigen, whereas the other cell line A549 has wild type active p53. 
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Figure 41. Model for CSC treatment induced resistance to carboplatin . 
In normal lung cells carboplatin induces caspase-dependent apoptosis. Long-term 
CSC treatment results in reduced expression of Smad3, which results in the up-
regulation of anti-apoptotic Bcl2 which creates resistance to carboplatin by blocking 
caspase-dependent apoptosis. This long-term CSC treated cell can be resensitized 
with BH3 mimitic, ABT-737. 
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In spite of this difference in p53 status, long-term CSC treatment makes the cells resistant 
to carboplatin treatment. Another genetic factor which might contribute to the sensitivity 
to carboplatin is K-ras which can activate various pathways namely PI3K/Akt, MAPK. 
A549 has a mutation in the K-ras, which makes it constitutively active. However, we saw 
carboplatin resistance in both the A549 and HPL1A cells. These studies demonstrate that 
the sensitivity to carboplatin is irrespective of the K-ras mutation status.  
The relationship between cell cycle arrest and cytotoxicity is complex and not 
fully deciphered. According to the current dogma, cell cycle arrest is seen as inhibitory to 
the cytotoxic process. This conclusion is derived primarily from the demonstration that 
pharmacological abrogation of the G2/M checkpoint increases cellular sensitivity to 
cisplatin (Demarcq, Bunch et al. 1994; O'Connor and Fan 1996). This is consistent with 
the concept that in response to DNA damage, the cell undergoes cell cycle arrest to 
enable the nucleotide excision repair (NER) complex to remove the adducts and thus 
promote cell survival. Cells undergo apoptosis only when repair is incomplete by 
excessive DNA damage. Similarly, we found that the long-term CSC treatment makes the 
cells arrest in the G2/M phase of cell cycle and as a result exhibited decreased apoptosis 
(Fig. 30 and 31). This could be due to the up-regulation of Bcl2. Recently, it has been 
shown that overexpression of Bcl2 is responsible the arrest of the cells in the G1/G2 
phase through the induction of cyclin-dependent kinase inhibitors namely, p27, p21, p16. 
We also demonstrated that the overexpression of Bcl2 that is observed in smokers with 
NSCLC, is not only an epiphenomenon but also is mechanistically involved in the 
development of carboplatin resistance (Fig. 32,33 and 34).  
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It has been shown that ABT-737, a BH3 mimetic, binds to anti-apoptotic Bcl2 
proteins and disrupts the sequestering and neutralizing of pro-apoptotic proteins namely, 
Bim and Bid. The drug has shown efficacy on administration as both a mono therapy and 
in combination with cytotoxic therapies. Even in our long-term CSC treated cell lines 
ABT-737 induced apoptosis, the putative reason for little induction of apoptosis may be 
due to the relatively high expression of Mcl1 in the cell lines (Fig.35A and B, lower 
panels). The sensitivity of ABT-737 to long-term CSC treated cells is not due to the 
decreased expression of anti-apoptotic Mcl1 as shown previously in some model systems. 
The differential sensitivity is possibly due to the high expression of Bcl2 from long-term 
CSC treatment as shown in previous studies (Tahir, Yang et al. 2007; Placzek, Wei et al. 
2010). The other niche for these drugs is in combination therapy where the Bcl2 
antagonist serves to inhibit Bcl2‐mediated resistance, enabling killing by conventional 
chemotherapy. In congruence to the previous studies, we illustrate that in our in vitro 
model (ABT-737) can improve the efficacy of Carboplatin. There is a strong indication 
that ABT-737 synergizes with Carboplatin, which is also in congruence to previous 
studies (Fig.36). 
In our previous study we showed that long-term CSC treatment caused a reduced 
expression of Smad3 and that caused the decrease in apoptosis. Our current results show 
that Smad3 regulates the expression of Bcl2 in our in vitro model system (Fig. 37A). This 
is in accordance to a previous publication showing Smad3 regulates the expression of 
Bcl2 in hepatocellular carcinoma (Yang, Zhang et al. 2006). Further, the regulation of 
Bcl2 expression levels by Smad3 has a causal effect of decreasing the I.C.50 of 
carboplatin by increasing the carboplatin-mediated apoptosis (Fig. 37B and 38). This is 
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also in agreement with in vivo studies that have shown that blocking TGF-β signaling can 
result in resistance to DNA-damaging agents including cisplatin (Stoika, Yakymovych et 
al. 2003; Kano, Bae et al. 2007). Bim, a pro-apoptotic factor, is another target of Smad3 
(Wildey, Patil et al. 2003). In our in vitro model we do not see any change in Bim levels 
(Fig. 29 C and D) even when Smad3 expression is reduced due to CSC treatment. It is 
quite possible that the regulation of Bim expression by Smad3 is context dependent. 
Along with the results (Fig. 39) and the observation that Bim levels are not changed by 
Smad3 in our model system, this demonstrates that Smad3 induces carboplatin resistance 
by regulating the expression of Bcl2. The in vitro results of the inverse relationship 
between the expression of Smad3 and Bcl2 also holds true in lung cancer patients at the 
mRNA level (Fig. 40). To our knowledge, this is the first time the inverse correlation 
between the two genes is shown in lung cancer (Fig. 40). It is worth exploring whether 
reduced expression of Smad3 and high expression of Bcl2 can serve as a prognostic or 
predictive biomarker for carboplatin based chemotherapy. Based on the observations, we 
propose a model that long-term CSC treatment induces an intrinsic resistance to 
carboplatin by upregulating the anti-apoptotic Bcl2 (Fig. 41). The upregulation of Bcl2 is 
induced by the reduced expression of Smad3.  This intrinsic resistance to carboplatin 
induced by long-term smoking can be overcome by treating with BH3 mimetics, ABT-
737. Additionally, from our data it would suggest that HDAC inhibitors namely, Sodium 
Buryrate may also resensitize the long-term CSC cells to carboplatin by restoring the 
expression of Smad3. 
Contemporary first-line chemotherapy in advanced stage lung cancer traditionally 
involves platinum-based drugs.  In lung cancer, resistance to cancer drugs presents a 
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major problem, limiting the effectiveness of chemotherapy. In the current era of 
personalized medicine, treatment selection for each cancer patient is becoming 
individualized or customized. There is a pressing need to identify predictive biomarkers 
for stratifying and subgrouping lung cancer patients for platinum-based therapy. Our 
results serve as examples of the utility of in vitro models for defining the subset of 
patients with favorable outcomes in cell line systems. After appropriate preclinical 
validation, these suggestions are expected to lead to a definitive subset of patients who 
would benefit from platinum-based chemotherapy or how the response of the resistant 
patients could be improved.  
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CHAPTER V 
 
CONCLUSION AND FUTURE DIRECTION 
 
Epidemiological studies have clearly established that tobacco products cause 
cancer of various types. Improving our understanding of the relevant carcinogenic 
mechanism will lead to new approaches for cancer prevention, early detection and 
perhaps improve therapy. Earlier diagnosis of patients with lung cancer would increase 
the number of potentially resectable patients, but better detection approaches are needed.  
Over the past two decades, several valuable tobacco-carcinogen biomarkers have been 
discovered, which have the potential to increase our mechanistic insights into lung 
carcinogenesis. Understanding the mechanisms by which smoking contributes to cancer 
has been and will remain, a major research focus. Several approaches have been taken, 
but none of them are full proof. Each system has its own tradeoffs.  
One of the in vivo approaches is to expose animals to cigarette smoke using a 
smoking chamber for extended period of time. One inherent problem to this approach is 
that, animals do not smoke the way as humans do.  Exposing the whole body animals to 
the smoking machines is more like passive smoke exposure than passive exposure.  This 
is more of a ―whole body exposure‖. Another problem is that other animal species do not 
breathe in the same manner as do people.  Rodents for example are obligate nose 
breathers. So the pattern of particle filtration in the nares and upper respiratory tract 
would be different than the mouth breathing in case of humans.  Thus, whereas use of 
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smoke is much more plausible than smoke extract as an exposure for animals in in vivo 
studies, but the model system imperfectly models human exposure. 
Another approach has been to capture the smoke emitted from a cigarette by 
bubbling it through an aqueous solution. Such preparation is called the cigarette smoke 
condensate. The exposure of cells to cigarette smoke condensate has its own trade offs. 
First the smoke condensate is different from routine smoke, since the volatile and rapidly 
reactive components are lost. A variety of chemical changes can take place with storage. 
Secondly, in vivo cells are not exposed to ―smoke‖ but rather to components of smoke 
that have been extracted to biological fluids.  Although the toxicity of individual 
components can be assessed, it is likely that the biological response to complex mixtures 
such as cigarette smoke is not the sum of multiple independent toxicities.  
Despite these noted methodologic limitations, studies using these techniques have 
provided great insight and are likely to continue to do so.  Over the past decade there are 
plenty of publications which suggest cigarette smoke condensate is capable of activating 
a variety of cell types, leading to production of a variety of mediators that have been 
suggested to play important roles in lung tumorigenesis.   
Our current work highlights that treatment of cells with cigarette smoke 
condensate for long term is a good model for studying the effect of long-term smoking in 
humans. On an average a person smokes for at least 50 pack years before the person 
actually develops lung cancer. So treating the cells for as short as 2 hours cannot 
correctly simulate the effects of long-term smoking. Our studies have uncovered two 
roles of long-term smoking in humans as summarized in Fig. 42.  
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In our first study we have shown that long-term CSC treatment results in reduced 
expression of Smad3. Smad3 expression is reduced both at the protein level and the 
mRNA level. Mechanistically, the expression of Smad3 is reduced due to accumulation 
of transcriptional repressor Sp1 on the Smad3 promoter. The treatment of histone 
deacetylase inhibitor, Sodium Butyrate removes Sp1 from the Smad3 promoter and thus 
brings back the expression of Smad3.  The biological effect of reduced expression of 
Smad3 was increased cell viability due to reduced apoptosis.  The decrease in apoptosis 
was due to the increased expression of anti-apoptotic Bcl2. Further, long-term CSC 
treatment enhanced tumorigenecity in A549 cells, partly through the down regulation of 
Smad3. Finally, we illustrated that in lung cancer patients the expression of Smad3 
mRNA was lower in smokers compared to non-smokers.  
In the second part of the study we show that the long-term CSC treatment to the 
cells makes the cells resistant to carboplatin. The cells become resistant due to the 
abrogation of induction of apoptosis by carboplatin.  We further show that Bcl2 is 
involved in making the cells resistant to carboplatin. We also illustrated that in our in 
vitro model system, Smad3 acts upstream of Bcl2 and regulates the expression of Bcl2 
and thus partially contributes to the resistance to carboplatin. This negative correlation 
between the expression of Smad3 and Bcl2 was valid in the mRNA levels too in lung 
cancer patients.  
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Figure 42. Summary of what the dissertation adds to the current knowledge.  
The top figure shows the scheme of link between lung cancer and tobacco-smoke 
carcinogens. Figure first published in (Hecht 2003). Our study adds to the existing model 
by adding the bottom part where the treatment of co-carcinogens and tumor promoters 
present in cigarette-smoke condensate results in decreased expression of Smad3 and thus 
imparts tumorigenecity and resistance to carboplatin in lung cancer patients.  
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Despite the impressive progress that has been made, there are still many problems. One 
of them is to diagnose the smokers who are susceptible to develop lung cancer.  Accurate 
measurement of specific carcinogen–DNA adducts in readily available samples is a 
significant challenge, which should be addressed as technology improves. It is also 
important to integrate carcinogen biomarkers into epidemiological studies. To reach this 
goal and obtain meaningful data, it is essential to develop methods that have adequate 
sensitivity and specificity for particular analytes and that are also amenable to high 
throughput analysis. A summary of the current molecular profiling approaches used now 
a days are shown in Fig.43. 
 
Figure 43. Molecular-Profiling Approaches to the Development of Personalized 
Therapy. Figure originally published in (Herbst, Heymach et. al, 2008) 
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Even though a lot of information have been gathered regarding the effect of tobacco 
carcinogens on lung tumorigenesis but still there are avenues which have not been 
pursued.  
1.  One of the most important questions might be which smoker will get cancer, given 
that an estimated 11-24% of smokers develop lung cancer. This question can be answered 
by looking at the levels of carcinogenic biomarker. The carcinogenic biomarker would 
help us identify the individuals who activate tobacco carcinogens more efficiently.  
2.  Here we have looked into how the expressions of the proteins are changed due to 
chronic CSC exposure. One other avenue could be to look at the mutation spectra of the 
genes with different time points of CSC treatment. There would be two different 
comparisons, one looking into the difference in the mutational spectra between 4 days, 
100 days and 300 days of CSC treatment. The second comparison would be between the 
4 days CSC and DMSO; 100-days CSC and DMSO and 300-day CSC and DMSO. From 
the mutational spectra we can get an idea about the novel if any pathways that are 
deregulated due to chronic CSC treatment. 
3. Another avenue that can be pursued would be to look into the expression of the 
microRNA‘s due to chronic CSC treatment. Here also we can look into how different 
time points of CSC exposure can change the expression patterns of the microRNA‘s. 
Then we can do an unsupervised clustering and get an idea about the pathways that are 
deregulated due to chronic CSC exposure. 
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